Protea Biosciences 10-K 14 Apr 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Apr. 13, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	Protea Biosciences Group, Inc.
Entity Central Index Key	1,335,103
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 16,010,330
Trading Symbol	PRGB
Entity Common Stock, Shares Outstanding		209,915,199

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 78,720	$ 6,450
Accounts receivable, less allowance for doubtful accounts of $7,000 and $3,900 as of December 31, 2016 and December 31, 2015, respectively	436,933	195,823
Inventory	92,244	111,087
Prepaid expenses	121,027	98,231
Total current assets	728,924	411,591
Property and equipment, net	2,466,125	2,626,907
Other noncurrent assets	19,041	5,248
Total Assets	3,214,090	3,043,746
Current Liabilities:
Current maturities on short and long-term debt, net of discount	4,012,149	1,323,594
Accounts payable	1,796,416	1,338,367
Bank line of credit	3,000,000	3,000,000
Obligations to stockholders, net of discount	3,087,956	2,574,500
Derivative liabilities	3,097,921	962,401
Other payables and accrued expenses	556,047	391,308
Total current liabilities	15,550,489	9,590,170
Long-term debt - net of current portion	1,769,355	1,726,158
Stockholders' Equity:
Preferred stock ($.0001 par value; 10,000,000 shares authorized; none are issued or outstanding at both December 31, 2016 and December 31, 2015)	0	0
Common stock ($.0001 par value; 500,000,000 shares authorized; 162,471,373 and 133,146,250 shares issued and outstanding at December 31, 2016 and December 31, 2015)	16,247	13,315
Additional paid in capital	81,123,483	71,311,572
Accumulated deficit	(95,245,530)	(79,597,608)
Accumulated other comprehensive income (loss)	46	139
Total Stockholders' Deficit	(14,105,754)	(8,272,582)
Total Liabilities and Stockholders' Deficit	$ 3,214,090	$ 3,043,746

Consolidated Balance Sheets _Pa

Consolidated Balance Sheets [Parenthetical] - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Allowance for Doubtful Accounts Receivable, Current	$ 7,000	$ 3,900
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	162,471,373	133,146,250
Common stock, shares outstanding	162,471,373	133,146,250

Consolidated Statements of Oper

Consolidated Statements of Operations and Total Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Gross revenue	$ 2,446,795	$ 1,861,802
Cost of revenue	(1,705,763)	(740,834)
Gross profit	741,032	1,120,968
Selling, general, administrative expenses	(5,631,978)	(6,923,228)
Research and development expense	(602,273)	(1,337,883)
Loss from operations	(5,493,219)	(7,140,143)
Other income (expense):
Gain on sale of equity method investment	1,502,100	910,000
Gain (losses) from disposal of assets	(10,521)	(42,506)
Gain from insurance recovery	45,952	0
Impairment Loss	(122,894)	0
Interest expense	(1,968,138)	(1,617,028)
Debt conversion inducement cost	0	(60,419)
Change in fair value of derivative	(9,602,437)	(1,631,586)
Other income and currency exchange income (expense)	1,235	7,248
Total other income (expense)	(10,154,703)	(2,434,291)
Loss before income taxes	(15,647,922)	(9,574,434)
Income taxes	0	0
Net loss	(15,647,922)	(9,574,434)
Foreign currency translation adjustment	(93)	429
Total comprehensive loss	$ (15,648,015)	$ (9,574,005)
Net loss per share - basic and diluted (in dollars per share)	$ (0.12)	$ (0.09)
Weighted average number of shares outstanding - basic and diluted (in shares)	136,058,595	109,699,034

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2014	$ (5,554,672)	$ 334	$ 6,659	$ 64,305,743	$ (69,867,118)	$ (290)
Balance (in shares) at Dec. 31, 2014		3,337,725	66,588,600
Issuance of preferred stock, net issuance costs	394,957	$ 37	$ 0	394,920	0	0
Issuance of preferred stock, net issuance costs (in shares)		370,050	0
Issuance of common stock, net issuance costs	1,112,303	$ 0	$ 569	1,111,734	0	0
Issuance of common stock, net issuance costs (in shares)		0	5,690,000
Stock dividend declared on preferred stock	0	$ 8	$ 0	156,048	(156,056)
Stock dividend declared on preferred stock (Shares)		78,040	0
Issuance of stock for services	544,630	$ 0	$ 201	544,429	0	0
Issuance of stock for services (in shares)		0	2,005,430
Issuance of stock for short-term convertible note	2,953,420	$ 0	$ 1,305	2,952,115	0	0
Issuance of stock for short-term convertible note (in shares)		0	13,051,058
Issuance of stock under anti-dilution provision	945,451	$ 0	$ 1,552	943,899	0	0
Issuance of stock under anti-dilution provision (in shares)		0	15,524,642
Conversion of preferred stock to common stock	0	$ (379)	$ 3,029	(2,650)	0	0
Conversion of preferred stock to common stock (Shares)		(3,785,815)	30,286,520
Stock-based compensation expense	267,638	$ 0	$ 0	267,638	0	0
Stock warrants issued for services and debt	517,843	0	0	517,843	0	0
Stock warrants issued as part of debt conversion inducement cost	60,419	0	0	60,419	0	0
Stock warrants issued to placement agent	175,694	0	0	175,694	0	0
Recognition of derivative liability	(116,260)	0	0	(116,260)	0	0
Net loss	(9,574,434)	0	0	0	(9,574,434)	0
Foreign currency translation adjustment	429	0	0	0	0	429
Balance at Dec. 31, 2015	(8,272,582)	$ 0	$ 13,315	71,311,572	(79,597,608)	139
Balance (in shares) at Dec. 31, 2015		0	133,146,250
Issuance of common stock, net issuance costs	1,108,296	$ 0	$ 1,877	1,106,419	0	0
Issuance of common stock, net issuance costs (in shares)		0	18,765,730
Issuance of stock upon conversion of accrued interest	92,841	$ 0	$ 37	92,804	0	0
Issuance of stock upon conversion of accrued interest (in shares)		0	371,364
Issuance of stock for services	467,620	$ 0	$ 356	467,264	0	0
Issuance of stock for services (in shares)		0	3,567,666
Issuance of stock for short-term convertible note	27,174	$ 0	$ 11	27,163	0	0
Issuance of stock for short-term convertible note (in shares)		0	108,696
Issuance of stock upon conversion of related party debt	5,000	$ 0	$ 6	4,994	0	0
Issuance of stock upon conversion of related party debt (in shares)		0	66,667
Issuance of stock under anti-dilution provision	6,429,375	$ 0	$ 0	6,429,375	0	0
Issuance of stock under anti-dilution provision (in shares)		0	0
Stock warrants exercised (cashless)	0	$ 0	$ 645	(645)	0	0
Stock warrants exercised (cashless) (in shares)		0	6,445,000
Warrants issued with short-term convertible notes	280,043	$ 0	$ 0	280,043	0	0
Anti-dilution warrant shares issued	1,044,420	0	0	1,044,420	0	0
Stock-based compensation expense	236,087	0	0	236,087	0	0
Stock warrants issued for services and debt	60,280	0	0	60,280	0	0
Stock warrants issued to placement agent	63,707	0	0	63,707	0	0
Net loss	(15,647,922)	0	0	0	(15,647,922)	0
Foreign currency translation adjustment	(93)	0	0	0	0	(93)
Balance at Dec. 31, 2016	$ (14,105,754)	$ 0	$ 16,247	$ 81,123,483	$ (95,245,530)	$ 46
Balance (in shares) at Dec. 31, 2016		0	162,471,373

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Equity (Deficit) [Parenthetical] - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Par or Stated Value Per Share	0.0001	$ 0.0001
Convertible Debentures [Member]
Issuance Cost		$ 309,345
Preferred Stock [Member]
Issuance Cost		$ 345,143
Common Stock [Member]
Common Stock, Par or Stated Value Per Share	$ 1	$ 0.0001
Issuance Cost	$ 299,134	$ 310,197

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (15,647,922)	$ (9,574,434)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	678,538	686,820
Impairment loss	122,894	0
Stock-based compensation expense	236,087	267,638
Issuance of Common Stock and warrants for services	527,900	609,103
Issuance of preferred and Common Stock for accrued interest	0	394,174
Accretion of original issue discount on short-term convertible note	639,215	500,000
Accretion of debt issue costs on short-term convertible notes	1,607,223	463,827
Capitalized interest on short-term convertible notes	100,688	0
Debt conversion inducement cost	0	60,419
Capitalized interest on debt modification	0	34,596
(Gain) Loss on disposal of assets	10,521	42,506
Gain on sale of investment	(1,502,100)	(910,000)
Gain from insurance recovery	(45,952)	0
Bad debt expense	19,000	119,230
Change in fair value of derivative liabilities	8,564,895	1,633,142
Net change in current assets and liabilities
Accounts receivable	(260,110)	78,091
Prepaid expenses	(22,796)	(44,209)
Inventory	41,723	146,550
Other noncurrent assets	(13,793)	(93,013)
Accounts payable	458,049	148,619
Other current liabilities	257,580	(127,513)
Net cash used in operating activities	(4,228,360)	(5,564,454)
Cash flows from investing activities:
Purchase of and deposits on equipment	(120,241)	(119,254)
Proceeds from sale of equipment	51,416	243,606
Proceeds from sale of investment	1,502,100	910,000
Proceeds from insurance recovery	45,952	0
Net cash provided by investing activities	1,479,227	1,034,352
Cash flows from financing activities:
Proceeds from advances from stockholder	627,439	1,402,500
Payments on advances from stockholder	(103,539)	(115,000)
Proceeds from issuances of debt to stockholders	0	200,000
Payments on debt with stockholders	(5,444)	0
Proceeds from issuances of short-term debt	2,886,000	2,000,000
Payments of short-term debt issuance costs	(330,141)	(309,345)
Payments of short-term debt (exchanged) issuance costs	(27,578)	0
Payments on debt	(902,783)	(193,415)
Payments on capital leases	(430,754)	(458,839)
Proceeds from sale of preferred stock, net	0	575,042
Proceeds from sale of Common Stock, net	1,108,296	1,112,303
Net cash provided by financing activities	2,821,496	4,213,246
Effect of exchange rate changes on cash	(93)	429
Net (decrease) in cash	72,270	(316,427)
Cash, beginning of period	6,450	322,877
Cash, end of period	78,720	6,450
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	317,580	317,545
Supplemental disclosure of non-cash investing and financing activities:
Equipment acquired by capital lease	605,226	516,382
Debt converted to preferred stock	0	2,953,420
Dividends paid in preferred stock	0	156,056
Issuance of Common Stock upon conversion of accrued interest	92,841	0
Issuance of Common Stock with short-term convertible notes	27,174	175,694
Issuance of warrants with short-term convertible notes	280,043	0
Issuance of Common Stock upon conversion of related party debt	5,000	0
Issuance of stock under anti-dilution provisions	6,429,375
Warrants to be issued to Placement Agent	63,707	0
Anti-dilution warrants to be issued	1,044,420	0
Debt issuance costs	$ 5,000	$ 0

Description of Company and Natu

Description of Company and Nature of Business	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	Protea Biosciences Group, Inc. (referred to as “Protea,” “the Company,” “we,” “us” and “our”) is an emerging growth molecular information company that has developed a revolutionary platform technology, which enables the direct analysis, mapping and display of biologically active molecules in living cells and tissue samples. The technology platform offers new, unprecedented capabilities useful to the pharmaceutical, diagnostic, clinical research, agricultural and life science industries. “Molecular information” refers to the generation and bioinformatic processing of very large data sets, known as “big data,” obtained by applying the Company’s technology to identify and characterize the proteins, metabolites, lipids and other molecules which are the biologically active molecular products of all living cells and life forms. Our technology is used to improve pharmaceutical development and life science research productivity and outcomes, and to extend and add value to other technologies that are used in research and development (“R&D”), such as three-dimensional tissue models, biomarker discovery, synthetic biologicals and mass spectrometry. In particular, the Company believes that its ability to rapidly provide comprehensive molecular image-based datasets addresses a universal need of the pharmaceutical, diagnostic and clinical research and life science industries. Going Concern The Company’s financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has funded its activities to date almost exclusively from debt and equity financings as well as sales of certain assets. Substantially all of the Company’s property and equipment are security for outstanding indebtedness. The Company will continue to require substantial funds to support our molecular information services business and advance global commercialization of our LAESI® instrument platform and service outstanding debt obligations, including scheduled interest and principal payments, and fulfilling payment obligations related to debt that has reached maturity. These factors raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects of the recoverability or classification of assets or the amounts and classification of liabilities that may result. The Company has experienced negative cash flows from operations since inception. Since inception, our operations have been funded primarily through proceeds received from the issuance of debt and sale of equity securities in private placement offerings and, from time-to-time, sales of certain assets. Management intends to continue to meet the Company’s operating cash flow by raising additional funds from the sale of equity and debt securities, the sale of certain assets, and possibly developing corporate development partnerships to advance our molecular information technology development activities by sharing the costs of development and commercialization. For example, we could also enter into a transaction such as a merger with a business that is complimentary to ours. We have also worked closely with various parties that financed our short- and long-term debt to obtain extensions and modifications that deferred or reduced amounts due under these obligations. Such extensions and modifications have included, in certain cases, the issuance of warrants. In addition, three members of the Company’s Board of Directors and the estate of a former board member guarantee payment of the Company’s outstanding bank line of credit. Such extensions, modifications and guarantees have been an important part of the Company’s ability to manage its liquidity and short-term capital resources. In addition, as part of these efforts, the Company has delayed payments to certain vendors and suppliers. As of December 31, 2016 the Company’s accounts payable balance of $ 1,796,416 1,652,009 1,503,966 1,503,966 10 October 15, 2016 On May 27, 2016, the Company filed a Form S-1 Registration Statement (“Form S-1”) with the SEC for a public offering of up to 3,100,000 15,000,000 On September 8, 2016, the Company entered into a note purchase agreement (the “Note Purchase Agreement”) with an “accredited investor” (as defined in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”) pursuant to which the investor purchased a 10 720,000 650,000 As discussed under Note 3 Bank Line of Credit, the Company has reclassified the outstanding balance of its bank line of credit to current liabilities as of September 30, 2016. As of that date, the outstanding balance of the line of credit was $ 3,000,000 On September 9, 2016, the Company reached an agreement with the holders of certain short-term convertible notes with a principal amount totaling $ 1,892,500 1,987,125 10 March 31, 2017 91,250 95,813 30,000 31,500 On September 26, 2016, the Company issued a 20 156,250 March 26, 2017 125,000 107,500 On October 31, 2016, the Company received an advance from a related party, an officer of the Company and a Board of Director. To provide the Company with $ 255,000 In November and December 2016, the Company issued 18,765,729 37,531,458 1,407,430 We have sold most our investment in AzurRx BioPharma, Inc. (“AzurRx”) as a means of obtaining additional cash. We raised proceeds of $ 1,502,100 25 1.7 125,757 100,000 1.00 Certain of the Company’s outstanding financial instruments contain anti-dilution provisions that may be triggered by the issuance of Common Stock or financial instruments such as Preferred Stock and warrants that are convertible or otherwise exchangeable for shares of the Company’s Common Stock. As a result of the November 2016 share issuances anti-dilution provisions under certain outstanding financial instruments have been triggered. Under such provisions the Company shall issue 85,724,996 Aside from further issuances of its Common Stock, the Company is exploring other options for obtaining additional financial resources such as the issuances of short-term debentures and Preferred Stock. There can be no assurance that we will be successful in raising enough funds to sustain operations. Since inception, we have been successful in raising funds and selling certain assets to fund our operations and believe that we will be successful in obtaining the necessary capital resources to fund our operations going forward; however, there can be no assurances that we will be able to secure any additional funding or capital resources or the terms and conditions of any such arrangements. These factors raise substantial doubt about our ability to continue as a going-concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The accompanying consolidated financial statements include the accounts of Protea Biosciences Group, Inc. and its wholly-owned subsidiary, Protea Biosciences, Inc. All material accounts and transactions have been eliminated in consolidation. The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. The Company has cash on deposit at banks that may exceed the federally-insured limits at times. Trade accounts receivable are reported at the amount management expects to collect from outstanding balances. Differences between the amount due and the amount management expects to collect are reported in the statement of operations of the year in which those differences are determined, with an offsetting entry to a valuation allowance for trade accounts receivable. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable. The Company performs ongoing credit evaluations of its customers and generally has not required collateral. The Company maintains allowances for doubtful accounts based on management’s analysis of historical losses from uncollectible accounts and risks identified for specific customers who may not be able to make required payments. If the financial condition of customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. An allowance of $ 7,000 3,000 Investments in AzurRx As a result of the sale of its subsidiary in 2014, the Company received 100 33 2,439,365 1,706,941 606,667 1,502,100 910,000 1.7 125,757 100,000 1.00 Inventory represents finished goods and work in progress. Finished goods and work in progress consist primarily of specifically identifiable items that are valued at the lower of cost or fair market value using the first-in, first-out (FIFO) method. December 31, 2016 December 31, 2015 Finished goods $ 8,725 $ 12,650 Work in progress 83,519 98,437 Total Inventory $ 92,244 $ 111,087 Expenditures for maintenance and repairs are charged to expense and the costs of significant improvements that extend the life of underlying assets are capitalized. Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows: Laboratory equipment 5 - 10 years Computers 5 years Leasehold improvements Life of lease Software 3 years December 31, 2016 December 31, 2015 Lab equipment $ 5,698,009 $ 6,617,038 Computer equipment 552,423 540,212 Office equipment 191,248 191,248 Leasehold improvements 212,730 212,730 6,654,410 7,561,228 Accumulated depreciation (4,188,285) (4,934,321) Property and equipment, net $ 2,466,125 $ 2,626,907 Depreciation expense is charged to either research and development or selling, general and administrative expenses and totals $ 678,538 686,820 The Company evaluates the potential impairment of property and equipment whenever events or changes in circumstances indicate that the carrying value of a group of assets may not be recoverable. An impairment loss would be recognized when the carrying amount of the asset group exceeds the estimated undiscounted future cash flows expected to be generated from the use of the asset group and its eventual disposition. The amount of impairment loss to be recorded is measured as the excess of the carrying value of the asset group over its fair value. Fair value is generally determined using a discounted cash flow analysis or market prices for similar assets. During 2016, the Company recognized an impairment expense of $ 122,894 December 31, 2016 December 31, 2015 Deposits $ 19,041 $ 5,248 Other noncurrent assets $ 19,041 $ 5,248 We follow the provisions of FASB ASC 605, “Revenue Recognition.” We recognize revenue of products when persuasive evidence of a sale arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred /title has passed, and collectability of the sales price is reasonably assured. The Company recognizes revenue from the sale of its ProteaPlot software when bundled with the LAESI platform, which facilitates operating the instrument and storage and display of datasets. The Company also recognizes revenue of standalone sales of ProteaPlot, which generally consists of additional user licenses. Revenue is recognized once the title is passed to the customer. We account for shipping and handling fees and costs in accordance with the provisions of FASB ASC 605-45-45, “Revenue Recognition - Principal Agent Considerations,” which requires all amounts charged to customers for shipping and handling to be classified as revenues. Shipping and handling costs charged to customers are recorded in the period the related product sales revenue is recognized. Regarding short-term service contracts, the majority of these service contracts involve the processing of imaging and bioanalytical samples for pharmaceutical and academic or clinical research laboratories. These contracts generally provide for a fixed fee for each method developed or sample processed and revenue is recognized when the analysis is complete and a report is delivered. For longer-term contracts involving multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. We perform this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) have standalone value to the customer, and the delivery or performance of the service(s) is probable and substantially in our control. Revenue on multiple revenue arrangements is recognized using a proportional method for each separately identified element. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or, if there is no predominant deliverable, upon delivery of the final element of the arrangement. Revenues from grants are based upon internal costs that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by the Company that is related to the grants. The Company has revenue from three major components: molecular information services, LAESI instrument platform, and research products. Year Ended December 31, 2016 December 31, 2015 Molecular information services $ 1,778,006 $ 929,076 LAESI instrument platform 358,334 640,060 Research products 310,455 292,666 Gross revenue $ 2,446,795 $ 1,861,802 A small number of customers have accounted for a substantial portion of our revenues in 2016. Six customers represented 53 22 December 31, 2016 December 31, 2015 Accrued expenses $ 68,411 $ 28,112 Accrued interest 264,507 108,731 Accrued warranties 45,000 50,000 Accrued payroll and benefits 119,619 124,183 Accrued sales tax 103 616 Unearned revenue 58,407 79,666 Other payables and accrued expenses $ 556,047 $ 391,308 The Company provides for a one-year warranty with the sale of its LAESI instrument. Additionally, the Company sells extended warranties for an additional cost. During 2016, the Company sold no extended LAESI warranties. All other product warranties are 90 days from the date of delivery of the goods. As the Company does not currently have sufficient historical data on warranty claims, the Company's estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its product. During the year ended December 31, 2016 and 2015, the Company recorded accrued warranty expense of $ 45,000 50,000 The Company records foreign currency adjustments resulting from international sales of its products and services are reflected in accumulated other comprehensive income (loss). The Company follows the policy of charging the costs of advertising to expense as incurred. The Company follows the policy of charging the costs of research and development to expense as incurred. Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Common share equivalents (which may consist of convertible preferred stock and dividends, options, warrants and convertible debt) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 185,501,000 77,317,000 Deferred income taxes are reported using the liability method. Deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Stock-Based Compensation The Company follows the provisions of FASB ASC 718, “ Stock-Based Compensation” Estimating the fair value for stock options for each grant requires judgment, including estimating stock-price volatility, expected term, expected dividends and risk-free interest rates. The expected volatility rates are estimated based on the volatility of similar entities whose share information is publicly available. The expected term represents the average time that options are expected to be outstanding and is estimated based on the average of the contractual term and the vesting period of the options as provided in SEC Staff Accounting Bulletin #110 as the “simplified” method. The risk-free interest rate for periods approximating the expected term of the options is based on the U.S. Treasury yield curve in effect at the time of grant. Expected dividends are zero as the Company has no plans to issue dividends on Common Stock. Due to a lack of trading history, the Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar companies considering their industry, stage of life cycle, size, and financial leverage. (See Note 8, Stock Options and Stock-Compensation). The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks; however, the Company has certain financial instruments that are embedded derivatives associated with capital raises and Common Stock purchase warrants. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 810-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity. We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities. Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable. Level 3 - inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of Common Stock warrants). The Company has entered into certain financial instruments and contracts such as, equity financing arrangements for the issuance of Common Stock, which include anti-dilution arrangements and detachable stock warrants that are (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. These instruments are recorded as derivative liabilities at fair value at the issuance date. Subsequent changes in fair value are recorded through the statement of operations. The Company’s derivative liabilities are related to Common Stock issuances, detachable Common Stock purchase warrants (“warrants”) issued in conjunction with debt and Common Stock, or warrants issued to the placement agents for financial instrument issuances. The Company estimates fair values of the warrants that do contain “Down Round Protections” utilizing valuation models and techniques that have been developed and are widely accepted that take into account the additional value inherent in “Down Round Protection.” These widely accepted techniques include “Modified Binomial,” “Monte Carlo Simulation” and the “Lattice Model.” The “core” assumptions and inputs to the “Binomial” model are the same as for “Black-Scholes,” such as trading volatility, remaining term to maturity, market price, strike price, and risk free rates; all Level 2 inputs. Fair value measurements are classified according to the lowest level input or value-driver that is significant to the valuation. A measurement may therefore be classified within Level 3 even though there may be significant inputs that are readily observable. However, a key input to a “Binomial” model (in our case, the “Monte Carlo Simulation” for which we engaged an independent valuation firm to perform) is the probability of a future capital raise. By definition, this input assumption does not meet the requirements for Level 1 or Level 2 outlined above; therefore, the entire fair value calculation is deemed to be Level 3 under accounting requirements due to this single Level 3 assumption. This input to the Monte Carlo Simulation model was developed with significant input from management based on its knowledge of the business, current financial position and the strategic business plan with its best efforts. As discussed above, financial liabilities are considered Level 3 when their fair values are determined using pricing models or similar techniques and at least one significant model assumption or input is unobservable. For the Company, the Level 3 financial liability is the derivative liability related to the Common Stock and warrants that include “Down Round Protection” and they were valued using the “Monte Carlo Simulation” technique. This technique, while the majority of inputs are Level 2, necessarily incorporates a Capital Raise Assumption which is unobservable and, therefore, a Level 3 input. December 31, 2016 Expected Probability of a Capital Life (Years) Risk Free Rate Volatility Raise Derivative liabilities 0.25-5.00 0.51% and 1.20% 81.62 % 100 % December 31, 2015 Expected Probability of a Capital Life (Years) Risk Free Rate Volatility Raise Derivative liabilities 2-3.33 0.16% and1.31% 75.54 % 100 % Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company’s derivative liabilities are related to Common Stock issuances, detachable warrants issued in conjunction with debt and Common Stock, or warrants issued to the placement agents for financial instrument issuances. Fair Value Measurements at December 31, 2016 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities - Common Stock $ 2,016,370 - - $ 2,016,370 Derivative liabilities - warrants 854,553 - - 854,553 Derivative liabilities – Convertible debentures 226,998 226,998 Total $ 3,097,921 $ - $ - $ 3,097,921 0.075 As a result of the November 2016 share issuances, anti-dilution provisions under certain outstanding financial instruments have been triggered, which was considered in the assumptions for future capital raise activity at December 31, 2016. Fair Value Measurements at December 31, 2015 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities - Common Stock $ 777,002 - - $ 777,002 Derivative liabilities - warrants 185,399 - - 185,399 Total $ 962,401 - - $ 962,401 For the year ended December 31, 2015, the Company revised its assessment of the probability of future down-rounds, due to a probability of closing on subsequent capital raises at levels that are unlikely, but could possibly result in anti-dilution triggers, currently at $ 0.25 Year Ended December 31, 2016 Total fair value Derivative liabilities measurements Common Convertible using Level 3 stock Warrants debt inputs Balance as of January 1, 2016 $ 777,002 $ 185,399 $ – $ 962,401 Issuance of warrants – 6,878 – 6,878 Anti-dilution shares to be issued (6,429,375) (1,044,420) – (7,473,795) Unrealized loss on derivative liabilities outstanding as of December 31, 2016 7,668,743 1,380,974 – 9,049,717 Fair value of variable conversion rate for convertible debentures issued in 2016 – – 226,998 226,998 Fair value of derivative liabilities associated with other financial instruments issued in 2016 – 325,722 – 325,722 Balance as of December 31, 2016 $ 2,016,370 $ 854,553 $ 226,998 $ 3,097,921 Year Ended December 31, 2015 Total Fair Value Derivative Derivative Measurements liabilities - liabilities - Using Level 3 Common Stock Warrants Inputs Balance as of December 31, 2014 $ 88,871 $ 65,187 $ 154,058 Issuance of warrants - 5,948 5,948 Anti-dilution shares to be issued (945,451) - (945,451) Unrealized (gain) loss on derivative liabilities 1,551,703 79,883 1,631,586 Recognition of derivative liabilities 81,879 34,381 116,260 Balance as of December 31, 2015 $ 777,002 $ 185,399 $ 962,401 In May 2014, the FASB issued ASU 2014-09, “ Revenue from Contracts with Customers (Topic 606) Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU 2016-08, “Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” (“ASU 2016-08”); ASU 2016-10, “Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing,” (“ASU 2016-10”); and ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” (“ASU 2016-20”), which are intended to provide additional guidance and clarity to ASU 2014-09. The Company must adopt ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20 along with ASU 2014-09 (collectively, the “New Revenue Standards”). The New Revenue Standards may be applied using one of two retrospective application methods: (1) a full retrospective approach for all periods presented, or (2) a modified retrospective approach that presents a cumulative effect as of the adoption date and additional required disclosures. The Company expects to adopt the New Revenue Standards in the first quarter of 2018. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements and related disclosures. In July 2015, the FASB issued ASU 2015-11, “ Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU 2016-02, “ Leases” (Topic 842) . In March 2016, the FASB issued ASU 2016-09 “ Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Accounting In August 2016, the FASB issued ASU 2016-18 “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Recepits and Cash Payments (a consensus of the Emerging Issues Task Force)

Bank Line of Credit

Bank Line of Credit	12 Months Ended
	Dec. 31, 2016
Bank Line of Credit [Abstract]
Bank Line of Credit [Text Block]	3. Bank Line of Credit The Company has a line of credit with a bank that is authorized to $ 3,000,000 The interest rate is variable and equal to 0.75% plus prime with a minimum rate of 5.87% per annum. July 12, 2018 3,000,000 14,675

Loans Payable to Stockholders

Loans Payable to Stockholders	12 Months Ended
	Dec. 31, 2016
Loan Payable [Abstract]
Loans Payable to Stockholders [Text Block]	4. Loans Payable to Stockholders During 2014, the Company received advances equal to an aggregate of $ 1,415,000 10 1,415,000 1,415,000 0.80 1,500,000 900,000 101,177 250,000 10,950 31 1,074,773 165,000 105,078 1,080,312 0.25 540,156 0.50 7,227 31,455 1,000,000 917,000 During 2015, the Company received aggregate gross proceeds of $ 200,000 10 December 31, 2015 25,000 March 31, 2016 0.33 90,910 200,000 12,500 9,729 During 2014, the Company received advances equal to an aggregate of $ 170,00 During 2015, the Company received advances equal to an aggregate of $ 1,402,500 115,000 57,500 1,400,000 During 2016, the Company received advances equal to an aggregate of $ 372,440 51,040 1,400,000 On October 31, 2016, the Company received a promissory note from a related party, an officer of the Company and a Board of Director. To provide the Company with $ 255,000 February 28, 2017 August 28, 2017 In December 2016, the Company’s Board of Directors authorized the conversion of an aggregate of $ 5,000 66,667 0.075 As of December 31, 2016, the outstanding balance of advances and other loans payable to stockholders was $ 3,087,956 1,111,556 1,721,400 255,000 See Note 6 Common Stock related to the conversion of accrued interest on promissory notes issued by the Company to Summit Resources, Inc. (“Summit”), an affiliate of Steve Antoline, a member of the Company’s Board of Directors, and accounts payable by the Company to Summit, into shares of Common Stock. See also Note 15 Evaluation of Subsequent Events for activity related to advances and other loans payable to stockholders after December 31, 2016.

Long-term Debt

Long-term Debt	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	5. Long-term Debt 1) Note Payable to the West Virginia Development Office (“WVDO”) In March 2007, the Company obtained an 8 685,000 3 96 8,035 1,057,167 As of December 31, 2016, the Company was ten months is arrears on scheduled principal and interest payments on an outstanding note payable to the West Virginia Development Office (“WVDO”). The deferral amount totaled $ 86,909 5,964 In February 2017, the Company and WVDO reached an agreement whereby the Company would defer payment for another year. See Note 15 Evaluation of Subsequent Events. 2) Note Payable to the West Virginia Economic Development Authority (“WVEDA”) In August 2009, the Company obtained a 10 242,631 4 120 2,457 The note was secured by 50% of equipment 531,522 33,880 1,832 1.5 1.5 3) Note Payable to the West Virginia Infrastructure and Jobs Development Council (“WVIJDC”) In August 2009, the Company obtained a 10 242,630 3.25 120 2,371 The note was secured by 50% of equipment 531,522 2,404 1,832 4) Note Payable to the West Virginia Economic Development Authority (“WVEDA”) In October 2010, the Company issued a 10 900,000 3.26 120 8,802 The note was secured by equipment 477,095 125,990 57,513 2016 1.5 1.5 5) Note Payable to the West Virginia Infrastructure & Jobs Development Council (“WVIJDC”) In December 2010, the Company issued a 10 900,000 3.25 120 8,781 The note was secured by equipment 1,098,249 8,902 57,513 6) Convertible Promissory Note Payable to the West Virginia Jobs Investment Trust Board (“WVJITB”) In March 2012, the Company issued an 18 290,000 6 2.00 72,500 100,000 190,000 October 31, 2014 In return for the extension, in February 2016, the Company granted WVJITB a five-year warrant to purchase 590,000 0.40 590,000 200,000 300,000 0.50 10.0 2,478 25,000 750,000 0.10 0.10 7) Convertible Promissory Note Payable to the West Virginia Jobs Investment Trust Board (“WVJITB”) In April 2012, the Company issued a 3 400,000 10 88,889 0.50 100,000 100,000 300,000 In return for the extension, in February 2016, the Company granted WVJITB a five-year warrant to purchase 590,000 shares of the Company’s Common Stock at an exercise price of $0.40 per share. Effective as of March 31, 2016, the Company and WVJITB entered into another addendum whereby the maturity dates of both promissory notes were extended to September 30, 2016. In return for the extension, the Company granted WVJITB another five-year warrant to purchase 590,000 shares of the Company’s Common Stock at an exercise price to be determined by the Board of Directors. This addendum also granted WVJITB the option to convert $200,000 of the $300,000 outstanding principal balance of the April 2012 Promissory Notes to Common Stock at $0.50 per share at or prior to the revised maturity date. The Company would be required to pay WVJITB the remaining (unconverted) principal balance and all accrued and unpaid interest in cash on September 30, 2016. The warrants granted to WVJITB (the warrant granted in February 2016 and the one granted in May 2016) expire upon the Company completing an underwritten offering that results in net cash proceeds to the Company of at least $10.0 million, if such a transaction is completed before the end of the five-year term. Regarding the warrant granted to WVJITB in February 2016 and May 2016, the relative fair value at the issuance date, and the corresponding liability recorded for the warrant, was estimated at $ 2,478 2,500 59,250 25,000 8) Note Payable to the West Virginia Economic Development Authority (“WVEDA”) In June 2012, the Company issued a 10 200,000 2 120 1,840 The note was secured by 50% of equipment 447,320 26,673 1.5 1.5 9) Short-Term Convertible Notes Issued in Second and Third Quarters 2016 and Related Exchange Notes In the second quarter of 2016, the Company issued a series of 20 1,950,000 1,560,000 448,750 415,000 605,000 481,250 390,000 10.0 0.25 0.25 85 10 156,250 On July 29, 2016, the Company sold to two Accredited Investors an aggregate face amount of $ 63,750 20 51,000 63,750 10 0.25 0.25 In addition, each of the investors received a three 75 0.325 731 In connection with the issuance of the Summer 2016 Convertible Debentures, the Company paid to a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) that acted as the placement agent an aggregate of approximately $ 191,400 1,409,625 0.25 three 3,077 On September 9, 2016, the Company reached an agreement with certain holders of the Second Quarter 2016 Convertible Debentures pursuant to which such debentures were exchanged for new short-term convertible notes (the “Exchange Notes”). The Exchange Notes shall have a principal amount totaling $ 1,987,125 10 In October and November 2016, the Company reached the same such agreement for the exchange of notes and warrants with three additional holders of the Summer 2016 Convertible Debentures. The Exchange Notes shall have a principal amount totaling $ 127,313 10 The relative fair value of the new warrants was estimated to be $ 306,231 10) September 2016 10% OID Secured Promissory Note On September 8, 2016, the Company entered into a Note Purchase Agreement with an Accredited Investor pursuant to which the investor purchased a 10 720,000 October 15, 2016 650,000 10 720,000 10 The Company’s obligations to repay and otherwise perform its obligations under the September 2016 10 On November 22, 2016, a payment of $ 240,000 480,000 12,467 11) September 2016 20% OID Note On September 26, 2016, the Company entered into a Subscription Agreement with an Accredited Investor pursuant to which the investor purchased a 20 156,250 125,000 20 156,250 10 March 26, 2017 0.25 0.25 85 468,750 0.325 1,792 20 In connection with such issuance, the Company paid to a broker dealer registered with FINRA that acted as the placement agent an aggregate of approximately $ 15,000 109,375 239 20 12) Short-Term Convertible Note issued in March 2016 On March 4, 2016, the Company issued to St. George Investments LLC (“St. George Investments”), an Accredited Investor, a 23 655,000 500,000 150,000 5,000 108,696 27,174 1,637,500 0.75 70 The relative fair value of the St. George Investments Warrant was estimated at $ 12,773 27,174 38,019 51,613 104,947 150,000 On September 6, 2016, the March 2016 Convertible Note reached maturity and the Company paid $ 655,000 10 In connection with the sale of the March 2016 Convertible Note, the Company paid to a Placement Agent an aggregate of approximately $ 60,000 491,250 0.25 2,456 13) Capital Leases In June 2016, the Company entered into a new four-year capital lease for three pieces of equipment that had a total estimated fair value of $ 549,543 From time to time, in the normal course of business, the Company enters into capital leases to finance equipment. As of December 31, 2016, the Company had seven capital lease obligations outstanding with imputed interest rates ranging from 5.86 9.45 1,868,809 13,793 Total outstanding debt, including capital lease obligations, are as follows (table excludes the outstanding balance of the bank line of credit because it was presented as a current liability, as discussed in Note 3 Bank Line of Credit; table also excludes obligations to stockholders, which are detailed in Note 4 Loans Payable to Stockholders and presented as a separate line item on the Company’s Consolidated Balance Sheets): December 31, 2016 December 31, 2015 1) Note Payable to the WVDO $ 92,873 $ 100,656 2) Note Payable to the WVEDA 143,312 143,312 3) Note Payable to the WVIJDC 139,229 139,229 4) Note Payable to the WVEDA 572,148 572,148 5) Note Payable to the WVIJDC 581,987 581,987 6) Note Payable to the WVJITB 290,000 290,000 7) Note Payable to the WVJITB 300,000 300,000 8) Note Payable to the WVEDA 168,362 168,362 9) Convertible Debenture 2 nd rd 2,114,438 - 10) September 10% OID Secured Promissory Note 480,000 - 11) September 2016 20% OID Note 156,250 - 12) Short-term Convertible Note in March 2016 - - 13) Capital leases 928,530 754,058 Total 5,967,129 3,049,752 Less: current portion (4,012,149) (1,323,594) Less: unamortized original issue discount (22,001) - Less: unamortized debt issuance costs (163,624) - Long-term portion $ 1,769,355 $ 1,726,158 Year ending December 31: Future required minimum principal repayments 2017 4,264,898 2018 539,235 2019 478,274 2020 333,970 2021 & Thereafter 350,752 Total $ 5,967,129

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Common Stock [Text Block]	6. Common Stock The Company is authorized to issue a total of 510,000,000 500,000,000 10,000,000 Common Stock - par value of $. 0001 As of December 31, 2016, the Company was authorized to issue a total of 510,000,000 500,000,000 0.0001 10,000,000 750,000,000 On December 1, 2015, the Company’s stockholders approved a Certificate of Amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of Common Stock, within a range of no less than one-for-fifteen (1:15) and no more than one-for-twenty-five (1:25), with such final ratio to be determined by the Board of Directors, in its sole discretion and with such reverse split to be effective at such time and date within one year after stockholder approval (the “Reverse Split”). In January 2017, the Board of Directors agreed to further the reverse stock split range to no less than one-for-fifteen (1:15) and no more than one-for-fifty (1:50), with such final ratio to be determined by the Board of Directors, in its sole discretion and with such reverse split to be effective at such time and date within one year after stockholder approval (the “Reverse Split”). See Note 15 Evaluation of Subsequent Events for additional information related to the expected ratio and timing for the Reverse Split. As of the date of this report, the Company’s Board of Directors had not enacted the Reverse Split and, therefore, the information presented in this report does not include the effects of any such transaction. See also Note 15 Evaluation of Subsequent Events related to the Company’s sale of Common Stock in first quarter 2017. Sale of Common Stock In November and December 2016 (the “Closing”), the Company received an aggregate of $ 1,407,430 140.74 Pursuant to its private placement memorandum, dated as of October 31, 2016 (the “Memorandum”), the Company is offering, through a placement agent, a maximum of 500 10,000 5,000,000 0.0001 133,333.33 0.09 133,333.33 0.1125 66,666,667 133,333,334 The Company intends to consummate a 1-for-50 reverse stock split of its outstanding Common Stock following the termination date of the Offering, which reverse split has previously been authorized by the Company’s stockholders. Consummation of the Reverse Stock Split will require (a) the filing of an amendment to the Company’s Certificate of Incorporation with the Delaware Secretary of State, and (b) obtaining the approval of FINRA. In connection with the Closings, the Company paid to the placement agent an aggregate of $ 186,132 5,367,320 0.075 In connection with the Closing, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with each of the Purchasers, which requires the Company to file a registration statement (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) registering for resale (i) all Common Stock issued to the Purchasers as part of the Units, (ii) all shares of Common Stock issuable upon exercise of the Investor Warrants and the warrants issued to the placement agent, and (iii) all shares of Common Stock issued to legal counsel for services rendered in connection with the Closing. If the Registration Statement is not declared effective by the SEC within the specified deadlines set forth in the Registration Rights Agreement, the Company will be required to pay to each Purchaser an amount in cash, as partial liquidated damages, equal to 1.0 6 18 The sale of Common Stock in November and December 2016 (see above) was completed at a unit price of $ 0.075 85,724,996 25,244,333 49,459,532 Conversion of Accrued Interest and Accounts Payable In February 2016, the Company’s Board of Directors authorized the conversion of an aggregate of $33,333 of accrued interest on promissory notes issued by the Company to Summit and $8,060 of account payable (or a total of $41,393) by the Company to Summit, into 165,573 shares of Common Stock at the rate of $0.25 per share. 450,000 0.40 945 In September 2016, the Company’s Board of Directors authorized the conversion of an aggregate of $ 41,667 9,781 51,448 205,791 0.25 In December 2016, the Company’s Board of Directors authorized the conversion of an aggregate of $ 5,000 66,667 0.075 5,480 In December 2016, the Company’s Board of Directors authorized the conversion of an aggregate of $ 50,000 666,667 0.075 54,800 Advertising Services Agreement In March 2016, the Company entered into an agreement with an advertising firm for certain services to be rendered to the Company over an estimated ninety (90) day period (the “Media Advertising Agreement”). Besides cash compensation, the Media Advertising Agreement required the Company to issue 150,000 150,000 37,500 In July 2016, the Company renewed the agreement with such advertising firm for certain services to be rendered to the Company over an estimated ninety (90) day period. Besides cash compensation, the Media Advertising Agreement required the Company to issue 300,000 75,000 Consulting Agreements In November 2016, the Company entered into a consulting agreement with a consulting firm for certain services to be rendered to the Company over a thirteen-month period (the “Agreement”). Besides cash compensation, the Agreement requires the Company to issue 500,000 500,000 0.11 250,00 250,000 250,000 27,500 On December 31 2016, the Company entered into a consulting agreement with a consultant to provide professional advisory and introductory services for a three-month period ending March 31, 2017, unless extend by mutual written agreement. In lieu of cash compensation, the Agreement requires the Company to issue the Consultant 250,000 30,000 On December 31, 2016, the Company entered into a consulting agreement with a consultant to provide business advisory services for a six-month period ending June 30, 2017. Besides reimbursement of reasonable and documented expenses, the Agreement requires the Company to issue 250,000 200,000 Directors Compensation On December 31, 2016, the Company issued certain Board of Directors shares of Common Stock as compensation for their work in 2016. This form of compensation was approved at the February 17, 2015 Board of Directors meeting. Price Value of Additional # Shares Par Per Gross Services Par Paid in Common Stock Issued Value Share Proceeds Obtained Value Capital (1) Balance at December 31, 2015 133,146,250 $ .0001 Various $ 58,393,786 $ 2,359,303 $ 13,315 $ 60,740,153 Issuance of stock (2) 18,765,730 .0001 $ 0.075 1,407,430 - 1,877 1,108,296 Issuance of stock (3) 371,364 .0001 $ 0.25 - 92,841 37 92,804 Issuance of stock (4) 3,567,666 .0001 $ Various - 467,620 356 467,264 Issuance of stock (5) 108,696 .0001 0.25 - 27,174 11 27,163 Issuance of stock (6) 66,667 .0001 $ 0.075 - 5,000 6 4,994 Issuance of stock (7) 6,445,000 .0001 $ 0.07047 - (645) 645 - Balance at December 31, 2016 162,471,373 $ 59,801,216 $ 2,951,293 $ 16,247 $ 62,440,674 (1) Balance does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options. (2) Shares issued under certain an anti-dilution provision per current offering provisions. (3) Shares issued for conversion of interest and accounts payment. Shares do not contain an anti-dilution provision. (4) Shares issued to directors for compensation for their service to the Company 1,417,666 1,350,000 666,667 133,333 (5) Shares issued to as part of debt services. Shares do not contain anti-dilution provision. (6) Shares issued for conversion of debt. Shares do not contain anti-dilution provision. (7) Shares issued for cashless exercise of warrants. Shares do not contain anti-dilution provision. Common Stock issues during 2015 are as follows: Price Value of Additional # Shares Par Per Gross Services Par Paid in Common Stock Issued Value Share Proceeds Obtained Value Capital (1) Balance at December 31, 2014 66,588,600 $ .0001 Various $ 53,708,521 $ 1,814,673 $ 6,659 $ 55,516,535 Issuance of stock (2) 13,051,058 .0001 $ 0.25 3,262,765 - 1,305 3,261,460 Issuance of stock (3) 30,286,520 .0001 $ 0.25 - - 3,029 (2,650) Issuance of stock (4) 15,524,642 .0001 $ 0.25 - - 1,552 (1,552) Issuance of stock (5) 1,134,520 .0001 Various - $ 319,630 114 319,516 Issuance of stock (6) 90,910 .0001 $ 0.33 - $ 30,000 9 29,991 Issuance of stock (7) 780,000 .0001 $ 0.25 - $ 195,000 78 194,922 Issuance of stock (8) 5,690,000 .0001 $ 0.25 1,422,500 - 569 1,421,931 Balance at December 31, 2015 133,146,250 $ 58,393,786 $ 2,359,303 $ 13,315 $ 60,740,153 (1) Balance does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options. (2) Shares issued for conversion of an aggregate of $ 2,841,085 394,173 27,506 (3) Conversion of preferred stock and accrued dividends into shares of Common Stock and contain an anti-dilution provision. (4) Shares issued under certain anti-dilution privileges. (5) Shares issued to consultants for services rendered. Shares do not contain anti-dilution provision. (6) Shares issued to a director as a commitment fee as part of Promissory Note. Shares do not contain anti-dilution provision. (7) Shares issued to directors for compensation for their service to the Company. Share do not contain anti-dilution provision. (8) Shares issued contain an anti-dilution provision that expire upon the earlier of 1) three years from date of issuance or 2) uplisting to a senior stock exchange.

Preferred Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Preferred Stock [Text Block]	7. Preferred Stock Preferred Stock - par value of $.0001 per share with one vote in respect of each share held. The Company is authorized to issue Preferred Stock in one or more series and containing such rights, privileges and limitations, including voting rights, dividend rates, conversion privileges, redemption rights and terms, redemption prices and liquidation preferences, as the Board may, from time to time, determine. No shares of the Preferred Stock were issued during 2016. Preferred Stock # Shares Par Price Gross Par Additional Balance at December 31, 2014 3,337,725 $ .0001 $ 2.00 $ 6,675,452 $ 334 $ 6,675,118 Issuance of stock (2) 370,050 .0001 $ 2.00 740,100 37 740,063 Stock dividend 78,040 .0001 $ 2.00 (156,056) 8 156,048 Conversion of preferred stock (3,785,815) .0001 $ 2.00 (7,259,496) (379) (7,571,229) Total December 31, 2015 - $ - $ - $ - (1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options. (2) Shares issued contain an anti-dilution provision expiring upon the conversion to Common Stock. During 2015, the Company sold units of Preferred Stock consisting of 50,000 200,000 0.375 2.00 0.25 6.0

Stock Options and Stock-based C

Stock Options and Stock-based Compensation	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options and Stock Based Compensation [Text Block]	8. Stock Options and Stock-based Compensation In 2002, the Board adopted the 2002 Equity Incentive Plan (“the 2002 Plan”) that governed equity awards to employees, directors and consultants of the Company. Under the Plan, 450,000 4,150,000 5,000,000 7,500,000 12,500,000 The types of awards permitted under the Plan include qualified incentive stock options (ISO) and non-qualified stock options (NQO), and restricted stock. Each option shall be exercisable at such times and subject to such terms and conditions as the Board may specify. Stock options generally vest over four years and expire no later than ten years from the date of grant. Weighted Average Weighted Average Remaining Shares Exercise Price Contractual Life (in years) Outstanding at December 31, 2014 7,019,750 $ 0.92 6.69 Granted 3,957,836 $ 0.33 Exercised - Cancelled or expired (927,500) $ 0.90 Outstanding at December 31, 2015 10,050,086 $ 0.69 7.26 Granted 3,350,000 $ 0.15 Exercised - Cancelled or expired (2,620,000) $ 0.52 Outstanding at December 31, 2016 10,780,086 $ 0.57 7.30 Exercisable at December 31, 2015 4,938,664 $ 1.01 5.59 Exercisable at December 31, 2016 5,680,899 $ 0.84 5.70 Options Outstanding Options Exercisable Exercise Price Outstanding Weighted Average Weighted Exercisable Weighted $ 0.15 3,250,000 203,125 $ 0.25 1,573,336 774,586 $ 0.48 150,000 46,875 $ 0.50 79,000 79,000 $ 0.53 405,000 151,875 $ 0.55 3,312,000 2,414,688 $ 1.25 150,000 150,000 $ 1.50 1,646,000 1,646,000 $ 2.00 214,750 214,750 $0.25 - $2.00 10,780,086 7.30 $ 0.57 5,680,899 $ 0.84 At December 31, 2016, the total aggregate intrinsic value for options currently exercisable and options outstanding was $ 0 0.12 Weighted Average Shares Grant-date Fair Value Nonvested at December 31, 2014 2,423,283 $ 0.258 Granted 3,957,836 $ 0.155 Forfeited (927,500) $ 0.386 Vested (342,197) $ 0.283 Nonvested at December 31, 2015 5,111,422 $ 0.153 Granted 3,350,000 $ 0.153 Forfeited (1,594,216) $ 0.314 Vested (1,526,519) $ 0.076 Nonvested at December 31, 2016 5,340,687 $ 0.125 The fair value of non-vested options to be recognized in future periods is $ 612,632 2.52 235,965 267,638 Year ended December 31, 2016 December 31, 2015 Selling, general, and administrative expense $ 222,195 $ 230,016 Research and development expense 13,892 37,622 Total stock-based compensation expense $ 236,087 $ 267,638 The weighted average grant-date fair value of options granted during the year ended December 31, 2016 was $ 0.0959 0.155 Year ended December 31, 2016 December 31, 2015 Risk-free interest rate 1.36 % 1.82 % Volatility factor 66.26 % 65.78 % Weighted average expected life (in years) 7 7 Dividend rate 0.0 % 0.0 % The Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar companies considering their industry, stage of life cycle, size, and financial leverage. Given the Company’s limited history with stock options, the Company’s expected term is based on an average of the contractual term and the vesting period of the options (the SAB 110 “Simplified” method).

Stock Warrants

Stock Warrants	12 Months Ended
	Dec. 31, 2016
Stock Warrants [Abstract]
Stock Warrants [Text Block]	9. Stock Warrants From 2008 through 2016, the Company issued warrants to purchase shares of Common Stock. The warrants are exercisable for three to five years from date of issuance and are exercisable at exercise prices that range from $ 0.075 2.25 In connection with the issuance of the Summer 2016 Convertible Debentures and the September 2016 20 0.325 6,510,001 1,519,000 On September 9, 2016, the Company reached an agreement with holders of certain short-term convertible notes issued in May and June 2016, the Second Quarter 2016 Convertible Debentures, to exchange existing notes with new short-term convertible notes (the “Exchange Notes”). In addition to the Exchange Notes, such holders are exchanging their existing warrants for warrants that contain full-ratchet anti-dilution provisions. No additional changes are being made to such forms of warrants. The relative fair value of the new warrants was estimated at $ 233,345 54,447 In October and November 2016, the Company reached an agreement with one holder of certain short-term convertible notes issued in May, the Second Quarter 2016 Convertible Debentures and an agreement with holders of certain short-term convertible notes issued in July 2016, the July 2016 Convertible Debentures, to exchange existing notes with new short-term convertible notes (the “Exchange Notes”). In addition to the Exchange Notes, such holders are exchanging their existing warrants for warrants that contain full-ratchet anti-dilution provisions. No additional changes are being made to such forms of warrants. The relative fair value of the new warrants was estimated at $ 14,950 3,488 The St. George Investments Warrant (see Note 5 Long-term Debt above for additional information related to this warrant and the related short-term convertible note) included an anti-dilution provision that required the Company to reduce the exercise price for the warrant for any subsequent issuances of Common Stock, or any instrument or securities that are convertible into or exercisable for shares of Common Stock, if the effective price for any such issuance was at an effective price per share that was less than the exercise price for the St. George Investments Warrant. Such a triggering event occurred upon issuance of the first of the Second and Third Quarter 2016 Convertible Debentures, each of which are convertible into shares of the Company’s Common Stock at $ 0.25 0.25 4,912,500 1,637,500 6,879 104,947 In November 2016, St George Investments provided notice of exercise of warrant to the Company and the cashless exercise option. Exhibit A in the Warrant to purchase shares of Common Stock. Upon review of the cashless exercise, the Company contacted legal counsel who in turn collaborated with St George Investments counsel. A settlement of 6,445,000 See Note 5 Long-term Debt and Note 6 Common Stock for information related to the issuance of warrants to Summit, WVJITB, and a placement agent for the purchase of 450,000 1,180,000 6,841,569 In November and December 2016, pursuant to the “Closing”, issued 18 18,765,729 0.09 18,765,729 0.1125 See also Note 15 Evaluation of Subsequent Events for information related to warrants issued in conjunction with the Company’s sale of Common Stock in January through March 2017. The sale of Common Stock in November and December 2016 (see above) was completed at a unit price of $ 0.075 85,724,996 25,244,336 0.075 49,459,532 In December 2016, the Company’s Board of Directors authorized the conversion of an aggregate of $ 5,000 66,667 0.075 18 66,667 0.09 66,667 0.1125 5,480 In December 2016, the Company’s Board of Directors authorized the conversion of an aggregate of $ 50,000 666,667 0.075 18 66,667 0.09 66,667 0.1125 As of December 31, 2016, warrants to purchase 122,475,881 202,982 Weighted Average Weighted Average Remaining Shares Exercise Price Contractual Life (in years) Outstanding at December 31, 2015 71,342,894 $ 0.77 2.37 Granted 60,435,862 $ 0.21 2.65 Exercised (4,912,500) - Cancelled or expired (4,390,375) $ 2.01 Outstanding at December 31, 2016 122,475,881 $ 0.43 2.13 Warrants Outstanding Weighted Average Remaining Weighted Average Exercise Price Outstanding Contractual Life (in years) Exercise Price $ 0.075 5,367,319 $ 0.09 19,632,396 $ 0.10 590,000 $ 0.1125 19,632,396 $ 0.25 4,808,145 $ 0.26 7,500,000 $ 0.30 2,845,000 $ 0.33 7,875,001 $ 0.35 14,831,098 $ 0.38 741,000 $ 0.40 1,040,000 $ 0.45 1,730,000 $ 0.50 2,250,523 $ 0.75 11,556,394 $ 0.80 1,602,500 $ 1.10 18,866,850 $ 1.12 263,750 $ 2.00 138,800 $ 2.20 98,320 $ 2.25 1,106,389 $0.075 - $2.25 122,475,881 2.13 $ 0.43

Treasury Stock

Treasury Stock	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Treasury Stock [Text Block]	10. Treasury Stock Treasury stock is accounted for using the par value method and is constructively cancelled when received.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	11. Income Taxes The provision for income taxes, if any, is comprised of current and deferred components. The current component, if any, presents the amount of federal and state income taxes that are currently reportable to the respective tax authorities and is measured by applying statutory rates to the Company’s taxable income as reported in its income tax returns. The Company has evaluated its income tax positions in accordance with FASB ASC 740. There were no changes to unrecognized tax benefits during 2014. The tax years 2011 through 2014 remain open to review by various taxing authorities. ASC Topic 740, Income Taxes defines the confidence level that a tax position must meet in order to be recognized in the financial statements. Accordingly, we have assessed uncertain tax positions in each of the tax jurisdictions in which we have operations and account for the related financial statement implications. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than 50% likelihood Significant management judgment is required in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded in connection with the deferred tax assets. The Company provides for a full valuation allowance against the deferred tax asset. Net operating loss carryforwards start to 76,530,000 68,600,000 We have recorded a full valuation allowance of $ 31,103,721 27,916,317 December 31, 2016 December 31, 2015 Current deferred income tax asset: Tax net operating loss carry forward $ 29,846,911 $ 26,751,533 Tax-deferred stock option expense 1,256,810 1,164,784 Total current deferred income tax asset 31,103,721 27,916,317 Valuation Allowance (31,103,721) (27,916,317) Net deferred income tax asset $ - $ - In the event that actual results differ from these estimates, or these estimates are adjusted in future periods, and realization of these deferred tax assets for which the valuation allowance has been provided occur, the provision for income taxes may decrease, raising income and positively impacting the Company’s financial position.

Lease Commitments

Lease Commitments	12 Months Ended
	Dec. 31, 2016
Leases [Abstract]
Lease Commitments [Text Block]	12. Lease Commitments The Company leases its facility under an operating lease beginning April 2012 through March 2017. The Company also has one equipment operating lease with a term of five years. Year ending Future minimum rental payments 2016 (payment in arrears) $ 21,754 2017 185,317 2018 189,613 2019 188,813 2020 184,813 2021 & Thereafter 369,626 Rent expense totals $ 167,633 274,580 On December 1, 2016, the Company executed the facility lease Renewal Option, Article IV-Possession, Renewal and Early Termination, 4.0.2 Renewal Option, for another five-year term starting April 1, 2017. On April 1, 2017, rent will increase $ 1,432 13,969 15,401

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2016
Postemployment Benefits [Abstract]
Retirement Plan [Text Block]	13. Retirement Plan The Company provides a 401(k) Profit Sharing Plan for elective deferrals whereby participants can defer up to 100% of their wages not to exceed a maximum dollar amount determined by the Federal Government each year. The Company, at its discretion, can make matching contributions to the Plan. The Company may also make qualified non-elective contributions to participants who are not highly compensated employees. All employees meeting age and hours of service requirements are eligible to participate in the Plan after completing one year of service. Participants become vested in employer contributions on a graduated scale with full vesting after five years. No Company contributions have yet been made.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Matters and Contingencies [Text Block]	14. Commitments and Contingencies Legal Proceedings The Company currently is not a party to any material legal proceeding and has no knowledge of any material legal proceeding contemplated by any governmental authority or third party. The Company may be subject to a number of claims and legal proceedings which, in the opinion of our management, are incidental to normal business operations. In managements’ opinion, although final settlement of these claims and suits may impact the financial statements in a particular period, they will not, in the aggregate, have a material adverse effect on the Company’s financial position, cash flows or results of operations. In 2016, the Company had received three court summons for past due accounts payables. The claims total $ 213,032 161,889.16 25,000 111,889.16 Subsequent to December 31, 2016, the Company made full and final payment of $ 111,889.16 37,000.00 Indemnity of Directors and Officers As permitted under Delaware law and required by corporate by-laws, the Company indemnifies and holds harmless its directors and officers for certain events or occurrences while the director or officer is or was serving in such capacity. The maximum potential amount of future payments that could be required under these indemnification obligations is unlimited; however, the Company maintains a Directors and Officers liability insurance policy that enables it to recover a portion of any future amounts paid with a limit of liability of $ 5,000,000 Agreement with Landlord On November 4, 2016, the Company reached an agreement with the landlord for its Morgantown, West Virginia facility for payment of past-due rent. The agreement stipulates that the Company will pay the amount due as of October 31, 2016, $ 90,801 Warranty Reserve The Company provides for a one-year warranty with the sale of its LAESI instrument. Additionally, the Company sells extended warranties for an additional cost. During 2016, the Company sold no extended LAESI warranties. All other product warranties are 90 days from the date of delivery of the goods. As the Company does not currently have sufficient historical data on warranty claims, the Company's estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its product. During the year ended December 31, 2016 and 2015, the Company recorded accrued warranty expense of $ 45,000 50,000 University License Agreements The Company has agreements with universities related to in-licensed technologies as follows: AGREEMENT WITH WEST VIRGINIA UNIVERSITY (WVU) The Company has entered into a License and Exclusive Option to License Agreement with the West Virginia University Research Corporation, a nonprofit West Virginia corporation (“WVURC”) acting for and on behalf of WVU. Under the terms of this Agreement, the WVURC has granted the Company an exclusive option to license technology from the laboratories of certain WVU principal investigators in the field of protein discovery for therapeutic, diagnostic and all other commercial fields worldwide. Under the terms of this Agreement, the Company pays expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenue resulting from the sale of products and services that utilize the WVU subject technology. AGREEMENT WITH GEORGE WASHINGTON UNIVERSITY (GWU) In December 2008, the Company entered into an Exclusive License Agreement with George Washington University (Washington D.C.) for technology developed in the laboratory of Dr. Akos Vertes Ph.D., Professor of Chemistry, Professor of Biochemistry & Molecular Biology, Founder and Co-Director of the W.M. Keck Institute for Proteomics Technology and Applications, the Department of Chemistry, who is a science advisor to the Company. The technology field is LAESI - laser ablation electrospray ionization, a new method of bioanalytical analysis that enables high throughput biomolecule characterization. Under the terms of the license agreement, the Company has the exclusive, worldwide rights to commercialize the technology. The Company is obligated to pay expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenues resulting from the sale of products and services that utilize the GWU subject technology. During the year ended December 31, 2016, the Company recorded royalty expenses of approximately $ 24,319 41,500 85,883 76,858 54,693 In November 2012, the Company entered into a Patent License Agreement with George Washington University (Washington D.C) for technology developed in the laboratory of Akos Vertes Ph.D. The technology field is Laser Desorption/Ionization and Peptide Sequencing on Laser-Induced Silicon Microcolumn Arrays (Matrix) and Nanophotonic Production, Modulation and Switching of Ions by Silicon Microcolumn Arrays. Under the terms of the license agreement, the Company has an exclusive, worldwide license to make, have made, use, import, offer for sale and sell the licensed products. The Company is obligated to pay a license initiation fee of $ 25,000 12,500 20,000 30,000 7 5 50 6 4 1,500 2,500 3,500 6,000 30,000 In January 2014, the Company became a subcontractor to GWU in a multi-year project with the Defense Advanced Research Projects Agency (“DARPA”) to develop new tools and methods to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within 30 days of exposure. During the year ended December 31, 2016, the Company recorded REDIchip royalty expense of $ 8,000 3,000 41,000 30,000 COAST Project In 2014, the Company entered into an agreement with Omics2Image related to the “Next Generation Ambient Imaging Mass Spectrometry for (Bio)polymers and Smart Materials” (“COAST Project”). The Company has committed to fund € 60,000 46,600 24,296 Engineering and Design Services The Company has engaged Dynamic Manufacturing LLC, to produce ten LAESI units and of December 31, 2016, the Company has received ten LAESI units. As of December 31, 2016, the Company has payables of $ 53,063

Evaluation of Subsequent Events

Evaluation of Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	15. Evaluation of Subsequent Events Sale of Common Stock In January through March 2017 (the “Closing”), the Company received an aggregate of $ 688,000 68.80 Pursuant to its private placement memorandum, dated as of October 31, 2016 (the “Memorandum”), the Company is offering, through a placement agent, a maximum of 500 10,000 5,000,000 0.0001 18 133,333.33 0.09 133,333.33 0.1125 66,666,667 133,333,334 In connection with the Closings, the Company paid to the placement agent an aggregate of $ 71,960 2,328,001 0.075 Stock Warrants Subsequent to December 31, 2016, the Company issued warrants to purchase 750,000 0.10 590,000 Consultant Agreements Subsequent to December 31, 2016, the Board of Directors approved payment of $ 50,000 666,667 0.075 666,667 0.09 666,667 0.1125 containing identical terms to the units of equity securities which we sold in our private placement to unaffiliated accredited investors between November 2016 and March 31, 2017. Subsequent to December 31, 2016, the Company issued warrants to purchase 1,720,000 Subsequent to December 31, 2016, the Company has issued an aggregate of 750,000 500,000 250,000 250,000 250,000 250,000 Subsequent to December 31, 2016, the Company has entered into a consulting agreement with a firm for professional financial advisory and introductory services for a period is from March 8, 2017 through December 31, 2017. Besides a one-time $ 10,000 1,200,000 Advances from Stockholders Subsequent to December 31, 2016, the Company received advances equal to an aggregate of $ 522,148 131,319 Conversion of Advances from Stockholders Subsequent to December 31, 2016, Related Parties agreed to convert $ 2,521,719 92,319 34,853,829 0.075 34,853,829 0.09 34,853,829 0.1125 Payment on Debt Subsequent to December 31, 2016, the Company made a $ 200,000 280,000 Stock Options Granted Subsequent to December 31, 2016, the Board of Directors approved 560,000 0.11 Appointment of Principal Officer Subsequent to December 31, 2016, the Board of Directors approved the appointment of Haddon Goodman to the Chief Business Officer, which was previously held by the Company’s President David Halverson. Obligations to Vendors Subsequent to December 31, 2016, the Company had fulfilled their obligation to MPR of $111,889 and such judgement has been cancelled. License Agreements with The George Washington University (“GWU”) Subsequent to December 31, 2016, the Company had received two Payment on Demand letters from George Washington University regarding the patent license agreement for “LISMA/NAPA License” and exclusive license agreement for the “LAESI License” along with the patent license agreement for the “Protein Microscope License.” As these letters relate to such agreements and past due payments they allow the Company to make payment or release their rights of the each of such license agreements by specified amount of days for each agreement or provide requested plans. The Protein Microscope License request is to deliver the University an updated Development Plan per article 2.1, achieving first commercial sale of the Licensed Product per article 2.3, and either demonstrating expenditures of agreed diligence minimums or paying any shortfall per article 2.4 within forty-five (45) days of the letter. The due date of this request is March 13, 2017. As of the date of this report the Company has complied with the request and is currently working with GWU. The LAESI License request is that all past due royalties are paid within sixty (60) days of the letter. George Washington University is preserving their rights under article 10.9 and 7.3(b) of the LAESI License agreement. The Company has made payment in full on March 28, 2017, this request has been fulfilled. The LISMA/NAPA License request is that all past due royalties are paid within ten (10) days of the letter. As of the date of this report, the Company has relinquished all rights to the LISMA/NAPA License and Patents. George Washington University has accepted this relinquishment and has started the process of removing Protea from all rights. Proxy Subsequent to December 31, 2016, our definitive proxy statement on Schedule 14A, filed as of March 2, 2017 with the SEC. We submitted a ratification of appointment of Schneider Downs & Co., Inc. as our auditors for the 2016 fiscal year, is being submitted to our stockholders for ratification as a matter of good corporate practice. If our stockholders fail to ratify the appointment, the Board of Directors will reconsider whether to appoint Schneider Downs & Co., Inc. Even if the appointment is ratified, the Board of Directors in its discretion may direct the appointment of a different independent registered public accounting firm if the Board of Directors determines that a new appointment would be in our best interests and the best interests of our stockholders. On January 31, 2017, at a special meeting of the Board of Directors, our Board of Directors approved by unanimous vote to seek shareholder approval of certain proposals by written consent that, to adopt and effectuate, will require the majority consent of our stockholders. As of the date of this filing on Form 10-K, we have submitted these proposals to our stockholders pursuant to our definitive proxy statement on Schedule 14A, filed on March 2, 2017 with the Securities and Exchange Commission ("SEC"). Under the proposals we are soliciting our stockholders written consent to approve the filing of an amended and restated certificate of incorporation in Delaware (“Restated Charter”), to increase the number of authorizes shares of our Common Stock, $ 0.0001 500,000,000 750,000,000 Included within our definitive proxy statement on Schedule 14A, filed as of March 2, 2017 with the SEC, we submitted a proposal to our stockholders for written consent to approve the filing of an amended and restated certificate of incorporation in Delaware (the “Restated Charter”) or in a subsequent amendment to the Restated Charter, provisions to effect a reverse split of our issued and outstanding Common Stock, within a range of not less than one-for-fifteen (1:15) and not more than one-for-fifty (1:50), with such ratio to be determined by the Board of Directors, in its sole discretion (the “Reverse Split”), and with such Reverse Split to be effective at such time and date within one year after the date such action is approved by the stockholders, if at all, as determined by the Board of Directors in its sole discretion (the “Reverse Split Proposal”). The Reverse Split proposal, including the final reduced number of shares of Common Stock into which our currently outstanding shares will be converted (within the stockholder-approved range referred to above), if approved by the consent of a majority of our stockholders, will be determined by our Board of Directors in order to list our Common Stock on the Nasdaq Capital Market which, in any event, shall become effective only (a) upon the approved filing of the Restated Charter to consummate the Reverse Split with the Secretary of State of the State of Delaware, including the final reduced number of shares of Common Stock into which our currently outstanding shares will be converted; and (b) upon announcement of the Reverse Split by FINRA. In the event that we receive written consent from a majority of our stockholders entitled to vote thereunder approving the Reverse Split and, subsequently, our Board of Directors elects to consummate the Reverse Split on or prior to March 31, 2017, the Board of Directors will not If implemented, the Reverse Stock Split will only effect our outstanding Common Stock and shares of Common Stock issuable upon conversion of convertible securities and exercise of warrants and options. It will not effect the number of shares of Common Stock we are authorized to issue under our Restated Charter. The purpose of the Reverse Split is to enable us to qualify our Common Stock for listing on a national stock exchange such as The Nasdaq Capital Market or the NYSE AMEX. Our Common Stock is currently traded on the OTC Markets OTCQB marketplace. Such trading market is considered to be less efficient than that provided by a stock exchange such as The Nasdaq Stock Market or NYSE AMEX. In order for us to list our Common Stock on The Nasdaq Stock Market or NYSE MKT, we must fulfill certain listing requirements, including minimum bid price requirements for our Common Stock. On April 4, 2017, the Company’s board of directors approved the Company’s decision to exercise such discretionary right by extending the deadline to receive written consents under the Consent Solicitation from the original date of March 30, 2017 to April 28, 2017. Convertible Note Subsequent to December 31, 2016, we issued our legal counsel, CKR Law LLP a $ 308,439 Senior Secured Convertible Note On April 7, 2017, we received a loan of $ 1,750,000 200,000 1,550,000 36 Of the loan proceeds, $ 1,250,000 30 500,000 5,000,000 Commencing 30 days after installation of the Instrument we will pay monthly installments of principal and accrued interest in the amount equal to the greater of (a) $ 62,030.86 monthly installments interest at the rate of 15% per annum), or (b) 20% of the cash proceeds we receive from customers who request services from the Company using the new mass spectrometer equipment. We also agreed to establish a special lock box to deposit cash proceeds we receive from use of such equipment. The Note is convertible into shares of our Common Stock, at the option of the holder at a conversion price equal to the lower 0.075 85 The loan is secured by a first lien and security interest on all of our assets and properties, including the purchased equipment and all purchase orders we receive in connection therewith.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Protea Biosciences Group, Inc. and its wholly-owned subsidiary, Protea Biosciences, Inc. All material accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Estimates and Assumptions The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. The Company has cash on deposit at banks that may exceed the federally-insured limits at times.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Trade Accounts Receivable Trade accounts receivable are reported at the amount management expects to collect from outstanding balances. Differences between the amount due and the amount management expects to collect are reported in the statement of operations of the year in which those differences are determined, with an offsetting entry to a valuation allowance for trade accounts receivable. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable. The Company performs ongoing credit evaluations of its customers and generally has not required collateral. The Company maintains allowances for doubtful accounts based on management’s analysis of historical losses from uncollectible accounts and risks identified for specific customers who may not be able to make required payments. If the financial condition of customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. An allowance of $ 7,000 3,000
Equity Method Investments, Policy [Policy Text Block]	Investments in AzurRx As a result of the sale of its subsidiary in 2014, the Company received 100 33 2,439,365 1,706,941 606,667 1,502,100 910,000 1.7 125,757 100,000 1.00
Inventory, Policy [Policy Text Block]	Inventory Inventory represents finished goods and work in progress. Finished goods and work in progress consist primarily of specifically identifiable items that are valued at the lower of cost or fair market value using the first-in, first-out (FIFO) method. December 31, 2016 December 31, 2015 Finished goods $ 8,725 $ 12,650 Work in progress 83,519 98,437 Total Inventory $ 92,244 $ 111,087
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Expenditures for maintenance and repairs are charged to expense and the costs of significant improvements that extend the life of underlying assets are capitalized. Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows: Laboratory equipment 5 - 10 years Computers 5 years Leasehold improvements Life of lease Software 3 years December 31, 2016 December 31, 2015 Lab equipment $ 5,698,009 $ 6,617,038 Computer equipment 552,423 540,212 Office equipment 191,248 191,248 Leasehold improvements 212,730 212,730 6,654,410 7,561,228 Accumulated depreciation (4,188,285) (4,934,321) Property and equipment, net $ 2,466,125 $ 2,626,907 Depreciation expense is charged to either research and development or selling, general and administrative expenses and totals $ 678,538 686,820 The Company evaluates the potential impairment of property and equipment whenever events or changes in circumstances indicate that the carrying value of a group of assets may not be recoverable. An impairment loss would be recognized when the carrying amount of the asset group exceeds the estimated undiscounted future cash flows expected to be generated from the use of the asset group and its eventual disposition. The amount of impairment loss to be recorded is measured as the excess of the carrying value of the asset group over its fair value. Fair value is generally determined using a discounted cash flow analysis or market prices for similar assets. During 2016, the Company recognized an impairment expense of $ 122,894
Other Receivables and Other Noncurrent assets [Policy Text Block]	Other Noncurrent assets December 31, 2016 December 31, 2015 Deposits $ 19,041 $ 5,248 Other noncurrent assets $ 19,041 $ 5,248
Revenue Recognition, Deferred Revenue [Policy Text Block]	Revenue Recognition We follow the provisions of FASB ASC 605, “Revenue Recognition.” We recognize revenue of products when persuasive evidence of a sale arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred /title has passed, and collectability of the sales price is reasonably assured. The Company recognizes revenue from the sale of its ProteaPlot software when bundled with the LAESI platform, which facilitates operating the instrument and storage and display of datasets. The Company also recognizes revenue of standalone sales of ProteaPlot, which generally consists of additional user licenses. Revenue is recognized once the title is passed to the customer. We account for shipping and handling fees and costs in accordance with the provisions of FASB ASC 605-45-45, “Revenue Recognition - Principal Agent Considerations,” which requires all amounts charged to customers for shipping and handling to be classified as revenues. Shipping and handling costs charged to customers are recorded in the period the related product sales revenue is recognized. Regarding short-term service contracts, the majority of these service contracts involve the processing of imaging and bioanalytical samples for pharmaceutical and academic or clinical research laboratories. These contracts generally provide for a fixed fee for each method developed or sample processed and revenue is recognized when the analysis is complete and a report is delivered. For longer-term contracts involving multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. We perform this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) have standalone value to the customer, and the delivery or performance of the service(s) is probable and substantially in our control. Revenue on multiple revenue arrangements is recognized using a proportional method for each separately identified element. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or, if there is no predominant deliverable, upon delivery of the final element of the arrangement. Revenues from grants are based upon internal costs that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by the Company that is related to the grants. The Company has revenue from three major components: molecular information services, LAESI instrument platform, and research products. Year Ended December 31, 2016 December 31, 2015 Molecular information services $ 1,778,006 $ 929,076 LAESI instrument platform 358,334 640,060 Research products 310,455 292,666 Gross revenue $ 2,446,795 $ 1,861,802 A small number of customers have accounted for a substantial portion of our revenues in 2016. Six customers represented 53 22
Other Payables and Accrued Expenses [Policy Text Block]	Other Payables and Accrued Expenses December 31, 2016 December 31, 2015 Accrued expenses $ 68,411 $ 28,112 Accrued interest 264,507 108,731 Accrued warranties 45,000 50,000 Accrued payroll and benefits 119,619 124,183 Accrued sales tax 103 616 Unearned revenue 58,407 79,666 Other payables and accrued expenses $ 556,047 $ 391,308
Standard Product Warranty, Policy [Policy Text Block]	Warranty Costs The Company provides for a one-year warranty with the sale of its LAESI instrument. Additionally, the Company sells extended warranties for an additional cost. During 2016, the Company sold no extended LAESI warranties. All other product warranties are 90 days from the date of delivery of the goods. As the Company does not currently have sufficient historical data on warranty claims, the Company's estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its product. During the year ended December 31, 2016 and 2015, the Company recorded accrued warranty expense of $ 45,000 50,000
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company records foreign currency adjustments resulting from international sales of its products and services are reflected in accumulated other comprehensive income (loss).
Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block]	Advertising The Company follows the policy of charging the costs of advertising to expense as incurred.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Credit The Company follows the policy of charging the costs of research and development to expense as incurred.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Common share equivalents (which may consist of convertible preferred stock and dividends, options, warrants and convertible debt) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 185,501,000 77,317,000
Income Tax, Policy [Policy Text Block]	Income Taxes Deferred income taxes are reported using the liability method. Deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company follows the provisions of FASB ASC 718, “ Stock-Based Compensation” Estimating the fair value for stock options for each grant requires judgment, including estimating stock-price volatility, expected term, expected dividends and risk-free interest rates. The expected volatility rates are estimated based on the volatility of similar entities whose share information is publicly available. The expected term represents the average time that options are expected to be outstanding and is estimated based on the average of the contractual term and the vesting period of the options as provided in SEC Staff Accounting Bulletin #110 as the “simplified” method. The risk-free interest rate for periods approximating the expected term of the options is based on the U.S. Treasury yield curve in effect at the time of grant. Expected dividends are zero as the Company has no plans to issue dividends on Common Stock. Due to a lack of trading history, the Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar companies considering their industry, stage of life cycle, size, and financial leverage. (See Note 8, Stock Options and Stock-Compensation).
Derivatives, Embedded Derivatives [Policy Text Block]	Derivative Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks; however, the Company has certain financial instruments that are embedded derivatives associated with capital raises and Common Stock purchase warrants. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 810-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity.
Fair Value Measurement, Policy [Policy Text Block]	Fair value of financial assets and liabilities - Derivative Instruments We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities. Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable. Level 3 - inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of Common Stock warrants). The Company has entered into certain financial instruments and contracts such as, equity financing arrangements for the issuance of Common Stock, which include anti-dilution arrangements and detachable stock warrants that are (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. These instruments are recorded as derivative liabilities at fair value at the issuance date. Subsequent changes in fair value are recorded through the statement of operations. The Company’s derivative liabilities are related to Common Stock issuances, detachable Common Stock purchase warrants (“warrants”) issued in conjunction with debt and Common Stock, or warrants issued to the placement agents for financial instrument issuances. The Company estimates fair values of the warrants that do contain “Down Round Protections” utilizing valuation models and techniques that have been developed and are widely accepted that take into account the additional value inherent in “Down Round Protection.” These widely accepted techniques include “Modified Binomial,” “Monte Carlo Simulation” and the “Lattice Model.” The “core” assumptions and inputs to the “Binomial” model are the same as for “Black-Scholes,” such as trading volatility, remaining term to maturity, market price, strike price, and risk free rates; all Level 2 inputs. Fair value measurements are classified according to the lowest level input or value-driver that is significant to the valuation. A measurement may therefore be classified within Level 3 even though there may be significant inputs that are readily observable. However, a key input to a “Binomial” model (in our case, the “Monte Carlo Simulation” for which we engaged an independent valuation firm to perform) is the probability of a future capital raise. By definition, this input assumption does not meet the requirements for Level 1 or Level 2 outlined above; therefore, the entire fair value calculation is deemed to be Level 3 under accounting requirements due to this single Level 3 assumption. This input to the Monte Carlo Simulation model was developed with significant input from management based on its knowledge of the business, current financial position and the strategic business plan with its best efforts. As discussed above, financial liabilities are considered Level 3 when their fair values are determined using pricing models or similar techniques and at least one significant model assumption or input is unobservable. For the Company, the Level 3 financial liability is the derivative liability related to the Common Stock and warrants that include “Down Round Protection” and they were valued using the “Monte Carlo Simulation” technique. This technique, while the majority of inputs are Level 2, necessarily incorporates a Capital Raise Assumption which is unobservable and, therefore, a Level 3 input. December 31, 2016 Expected Probability of a Capital Life (Years) Risk Free Rate Volatility Raise Derivative liabilities 0.25-5.00 0.51% and 1.20% 81.62 % 100 % December 31, 2015 Expected Probability of a Capital Life (Years) Risk Free Rate Volatility Raise Derivative liabilities 2-3.33 0.16% and1.31% 75.54 % 100 % Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company’s derivative liabilities are related to Common Stock issuances, detachable warrants issued in conjunction with debt and Common Stock, or warrants issued to the placement agents for financial instrument issuances. Fair Value Measurements at December 31, 2016 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities - Common Stock $ 2,016,370 - - $ 2,016,370 Derivative liabilities - warrants 854,553 - - 854,553 Derivative liabilities – Convertible debentures 226,998 226,998 Total $ 3,097,921 $ - $ - $ 3,097,921 The Company’s assessment of the probability of future capital raises is considered to be high. Such capital raise activities are estimated to take place at levels that could possibly result in anti-dilution triggers—currently at $ 0.075 As a result of the November 2016 share issuances, anti-dilution provisions under certain outstanding financial instruments have been triggered, which was considered in the assumptions for future capital raise activity at December 31, 2016. Fair Value Measurements at December 31, 2015 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities - Common Stock $ 777,002 - - $ 777,002 Derivative liabilities - warrants 185,399 - - 185,399 Total $ 962,401 - - $ 962,401 For the year ended December 31, 2015, the Company revised its assessment of the probability of future down-rounds, due to a probability of closing on subsequent capital raises at levels that are unlikely, but could possibly result in anti-dilution triggers, currently at $ 0.25 Year Ended December 31, 2016 Total fair value Derivative liabilities measurements Common Convertible using Level 3 stock Warrants debt inputs Balance as of January 1, 2016 $ 777,002 $ 185,399 $ – $ 962,401 Issuance of warrants – 6,878 – 6,878 Anti-dilution shares to be issued (6,429,375) (1,044,420) – (7,473,795) Unrealized loss on derivative liabilities outstanding as of December 31, 2016 7,668,743 1,380,974 – 9,049,717 Fair value of variable conversion rate for convertible debentures issued in 2016 – – 226,998 226,998 Fair value of derivative liabilities associated with other financial instruments issued in 2016 – 325,722 – 325,722 Balance as of December 31, 2016 $ 2,016,370 $ 854,553 $ 226,998 $ 3,097,921 Year Ended December 31, 2015 Total Fair Value Derivative Derivative Measurements liabilities - liabilities - Using Level 3 Common Stock Warrants Inputs Balance as of December 31, 2014 $ 88,871 $ 65,187 $ 154,058 Issuance of warrants - 5,948 5,948 Anti-dilution shares to be issued (945,451) - (945,451) Unrealized (gain) loss on derivative liabilities 1,551,703 79,883 1,631,586 Recognition of derivative liabilities 81,879 34,381 116,260 Balance as of December 31, 2015 $ 777,002 $ 185,399 $ 962,401
New Accounting Pronouncements, Policy [Policy Text Block]	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In May 2014, the FASB issued ASU 2014-09, “ Revenue from Contracts with Customers (Topic 606) Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU 2016-08, “Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” (“ASU 2016-08”); ASU 2016-10, “Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing,” (“ASU 2016-10”); and ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” (“ASU 2016-20”), which are intended to provide additional guidance and clarity to ASU 2014-09. The Company must adopt ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20 along with ASU 2014-09 (collectively, the “New Revenue Standards”). The New Revenue Standards may be applied using one of two retrospective application methods: (1) a full retrospective approach for all periods presented, or (2) a modified retrospective approach that presents a cumulative effect as of the adoption date and additional required disclosures. The Company expects to adopt the New Revenue Standards in the first quarter of 2018. The Company is currently in the process of evaluating the impact of adoption of this standard on our consolidated financial statements and related disclosures. In July 2015, the FASB issued ASU 2015-11, “ Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU 2016-02, “ Leases” (Topic 842) . In March 2016, the FASB issued ASU 2016-09 “ Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Accounting In August 2016, the FASB issued ASU 2016-18 “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Recepits and Cash Payments (a consensus of the Emerging Issues Task Force)

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following at: December 31, 2016 December 31, 2015 Finished goods $ 8,725 $ 12,650 Work in progress 83,519 98,437 Total Inventory $ 92,244 $ 111,087
Property Plant And Equipment Useful Life [Table Text Block]	Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows: Laboratory equipment 5 - 10 years Computers 5 years Leasehold improvements Life of lease Software 3 years
Property, Plant and Equipment [Table Text Block]	Property and equipment consists of the following at: December 31, 2016 December 31, 2015 Lab equipment $ 5,698,009 $ 6,617,038 Computer equipment 552,423 540,212 Office equipment 191,248 191,248 Leasehold improvements 212,730 212,730 6,654,410 7,561,228 Accumulated depreciation (4,188,285) (4,934,321) Property and equipment, net $ 2,466,125 $ 2,626,907
Summary of Trade and Other Receivables [Table Text Block]	Other receivables, which reflect amounts from non-trade activity and other noncurrent assets, consist of the following at: December 31, 2016 December 31, 2015 Deposits $ 19,041 $ 5,248 Other noncurrent assets $ 19,041 $ 5,248
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Revenue by component was as follows: Year Ended December 31, 2016 December 31, 2015 Molecular information services $ 1,778,006 $ 929,076 LAESI instrument platform 358,334 640,060 Research products 310,455 292,666 Gross revenue $ 2,446,795 $ 1,861,802
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Other payables and accrued expenses, which reflect amounts due from non-trade activity, consist of the following at: December 31, 2016 December 31, 2015 Accrued expenses $ 68,411 $ 28,112 Accrued interest 264,507 108,731 Accrued warranties 45,000 50,000 Accrued payroll and benefits 119,619 124,183 Accrued sales tax 103 616 Unearned revenue 58,407 79,666 Other payables and accrued expenses $ 556,047 $ 391,308
Fair Value Inputs, Instruments Classified in Shareholders Equity, Quantitative Information [Table Text Block]	A range of key quantitative assumptions related to the Common Stock and warrants issued during 2016 and 2015 are as follows: December 31, 2016 Expected Probability of a Capital Life (Years) Risk Free Rate Volatility Raise Derivative liabilities 0.25-5.00 0.51% and 1.20% 81.62 % 100 % December 31, 2015 Expected Probability of a Capital Life (Years) Risk Free Rate Volatility Raise Derivative liabilities 2-3.33 0.16% and1.31% 75.54 % 100 %
Fair Value, by Balance Sheet Grouping [Table Text Block]	The derivative liabilities measured at fair value on a recurring basis are summarized below: Fair Value Measurements at December 31, 2016 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities - Common Stock $ 2,016,370 - - $ 2,016,370 Derivative liabilities - warrants 854,553 - - 854,553 Derivative liabilities – Convertible debentures 226,998 226,998 Total $ 3,097,921 $ - $ - $ 3,097,921 Fair Value Measurements at December 31, 2015 Carrying Value Level 1 Level 2 Level 3 Derivative liabilities - Common Stock $ 777,002 - - $ 777,002 Derivative liabilities - warrants 185,399 - - 185,399 Total $ 962,401 - - $ 962,401
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis: Year Ended December 31, 2016 Total fair value Derivative liabilities measurements Common Convertible using Level 3 stock Warrants debt inputs Balance as of January 1, 2016 $ 777,002 $ 185,399 $ – $ 962,401 Issuance of warrants – 6,878 – 6,878 Anti-dilution shares to be issued (6,429,375) (1,044,420) – (7,473,795) Unrealized loss on derivative liabilities outstanding as of December 31, 2016 7,668,743 1,380,974 – 9,049,717 Fair value of variable conversion rate for convertible debentures issued in 2016 – – 226,998 226,998 Fair value of derivative liabilities associated with other financial instruments issued in 2016 – 325,722 – 325,722 Balance as of December 31, 2016 $ 2,016,370 $ 854,553 $ 226,998 $ 3,097,921 Year Ended December 31, 2015 Total Fair Value Derivative Derivative Measurements liabilities - liabilities - Using Level 3 Common Stock Warrants Inputs Balance as of December 31, 2014 $ 88,871 $ 65,187 $ 154,058 Issuance of warrants - 5,948 5,948 Anti-dilution shares to be issued (945,451) - (945,451) Unrealized (gain) loss on derivative liabilities 1,551,703 79,883 1,631,586 Recognition of derivative liabilities 81,879 34,381 116,260 Balance as of December 31, 2015 $ 777,002 $ 185,399 $ 962,401

Long-term Debt (Tables)

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	Total debts outstanding are as follows: December 31, 2016 December 31, 2015 1) Note Payable to the WVDO $ 92,873 $ 100,656 2) Note Payable to the WVEDA 143,312 143,312 3) Note Payable to the WVIJDC 139,229 139,229 4) Note Payable to the WVEDA 572,148 572,148 5) Note Payable to the WVIJDC 581,987 581,987 6) Note Payable to the WVJITB 290,000 290,000 7) Note Payable to the WVJITB 300,000 300,000 8) Note Payable to the WVEDA 168,362 168,362 9) Convertible Debenture 2 nd rd 2,114,438 - 10) September 10% OID Secured Promissory Note 480,000 - 11) September 2016 20% OID Note 156,250 - 12) Short-term Convertible Note in March 2016 - - 13) Capital leases 928,530 754,058 Total 5,967,129 3,049,752 Less: current portion (4,012,149) (1,323,594) Less: unamortized original issue discount (22,001) - Less: unamortized debt issuance costs (163,624) - Long-term portion $ 1,769,355 $ 1,726,158
Schedule of Maturities of Long-term Debt [Table Text Block]	Future required minimum principal repayments over the next five years are as follows: Year ending December 31: Future required minimum principal repayments 2017 4,264,898 2018 539,235 2019 478,274 2020 333,970 2021 & Thereafter 350,752 Total $ 5,967,129

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2016
Common Stock [Member]
Schedule of Stock by Class [Table Text Block]	Common Stock issues during 2016 are as follows: Price Value of Additional # Shares Par Per Gross Services Par Paid in Common Stock Issued Value Share Proceeds Obtained Value Capital (1) Balance at December 31, 2015 133,146,250 $ .0001 Various $ 58,393,786 $ 2,359,303 $ 13,315 $ 60,740,153 Issuance of stock (2) 18,765,730 .0001 $ 0.075 1,407,430 - 1,877 1,108,296 Issuance of stock (3) 371,364 .0001 $ 0.25 - 92,841 37 92,804 Issuance of stock (4) 3,567,666 .0001 $ Various - 467,620 356 467,264 Issuance of stock (5) 108,696 .0001 0.25 - 27,174 11 27,163 Issuance of stock (6) 66,667 .0001 $ 0.075 - 5,000 6 4,994 Issuance of stock (7) 6,445,000 .0001 $ 0.07047 - (645) 645 - Balance at December 31, 2016 162,471,373 $ 59,801,216 $ 2,951,293 $ 16,247 $ 62,440,674 (1) Balance does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options. (2) Shares issued under certain an anti-dilution provision per current offering provisions. (3) Shares issued for conversion of interest and accounts payment. Shares do not contain an anti-dilution provision. (4) Shares issued to directors for compensation for their service to the Company 1,417,666 1,350,000 666,667 133,333 (5) Shares issued to as part of debt services. Shares do not contain anti-dilution provision. (6) Shares issued for conversion of debt. Shares do not contain anti-dilution provision. (7) Shares issued for cashless exercise of warrants. Shares do not contain anti-dilution provision. Common Stock issues during 2015 are as follows: Price Value of Additional # Shares Par Per Gross Services Par Paid in Common Stock Issued Value Share Proceeds Obtained Value Capital (1) Balance at December 31, 2014 66,588,600 $ .0001 Various $ 53,708,521 $ 1,814,673 $ 6,659 $ 55,516,535 Issuance of stock (2) 13,051,058 .0001 $ 0.25 3,262,765 - 1,305 3,261,460 Issuance of stock (3) 30,286,520 .0001 $ 0.25 - - 3,029 (2,650) Issuance of stock (4) 15,524,642 .0001 $ 0.25 - - 1,552 (1,552) Issuance of stock (5) 1,134,520 .0001 Various - $ 319,630 114 319,516 Issuance of stock (6) 90,910 .0001 $ 0.33 - $ 30,000 9 29,991 Issuance of stock (7) 780,000 .0001 $ 0.25 - $ 195,000 78 194,922 Issuance of stock (8) 5,690,000 .0001 $ 0.25 1,422,500 - 569 1,421,931 Balance at December 31, 2015 133,146,250 $ 58,393,786 $ 2,359,303 $ 13,315 $ 60,740,153 (1) Balance does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options. (2) Shares issued for conversion of an aggregate of $ 2,841,085 394,173 27,506 (3) Conversion of preferred stock and accrued dividends into shares of Common Stock and contain an anti-dilution provision. (4) Shares issued under certain anti-dilution privileges. (5) Shares issued to consultants for services rendered. Shares do not contain anti-dilution provision. (6) Shares issued to a director as a commitment fee as part of Promissory Note. Shares do not contain anti-dilution provision. (7) Shares issued to directors for compensation for their service to the Company. Share do not contain anti-dilution provision. (8) Shares issued contain an anti-dilution provision that expire upon the earlier of 1) three years from date of issuance or 2) uplisting to a senior stock exchange.

Preferred Stock (Tables)

Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2016
Preferred Stock [Member]
Schedule of Stock by Class [Table Text Block]	Preferred Stock issues during 2015 are as follows: Preferred Stock # Shares Par Price Gross Par Additional Balance at December 31, 2014 3,337,725 $ .0001 $ 2.00 $ 6,675,452 $ 334 $ 6,675,118 Issuance of stock (2) 370,050 .0001 $ 2.00 740,100 37 740,063 Stock dividend 78,040 .0001 $ 2.00 (156,056) 8 156,048 Conversion of preferred stock (3,785,815) .0001 $ 2.00 (7,259,496) (379) (7,571,229) Total December 31, 2015 - $ - $ - $ - (1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options. (2) Shares issued contain an anti-dilution provision expiring upon the conversion to Common Stock.

Stock Options and Stock-based28

Stock Options and Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of stock option activity is as follows: Weighted Average Weighted Average Remaining Shares Exercise Price Contractual Life (in years) Outstanding at December 31, 2014 7,019,750 $ 0.92 6.69 Granted 3,957,836 $ 0.33 Exercised - Cancelled or expired (927,500) $ 0.90 Outstanding at December 31, 2015 10,050,086 $ 0.69 7.26 Granted 3,350,000 $ 0.15 Exercised - Cancelled or expired (2,620,000) $ 0.52 Outstanding at December 31, 2016 10,780,086 $ 0.57 7.30 Exercisable at December 31, 2015 4,938,664 $ 1.01 5.59 Exercisable at December 31, 2016 5,680,899 $ 0.84 5.70
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information about stock options at December 31, 2016: Options Outstanding Options Exercisable Exercise Price Outstanding Weighted Average Weighted Exercisable Weighted $ 0.15 3,250,000 203,125 $ 0.25 1,573,336 774,586 $ 0.48 150,000 46,875 $ 0.50 79,000 79,000 $ 0.53 405,000 151,875 $ 0.55 3,312,000 2,414,688 $ 1.25 150,000 150,000 $ 1.50 1,646,000 1,646,000 $ 2.00 214,750 214,750 $0.25 - $2.00 10,780,086 7.30 $ 0.57 5,680,899 $ 0.84
Schedule of Nonvested Share Activity [Table Text Block]	The following table summarizes the activity of the Company’s stock options that have not vested for the year ended December 31, 2016: Weighted Average Shares Grant-date Fair Value Nonvested at December 31, 2014 2,423,283 $ 0.258 Granted 3,957,836 $ 0.155 Forfeited (927,500) $ 0.386 Vested (342,197) $ 0.283 Nonvested at December 31, 2015 5,111,422 $ 0.153 Granted 3,350,000 $ 0.153 Forfeited (1,594,216) $ 0.314 Vested (1,526,519) $ 0.076 Nonvested at December 31, 2016 5,340,687 $ 0.125
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense is as follows: Year ended December 31, 2016 December 31, 2015 Selling, general, and administrative expense $ 222,195 $ 230,016 Research and development expense 13,892 37,622 Total stock-based compensation expense $ 236,087 $ 267,638
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the option grants was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions: Year ended December 31, 2016 December 31, 2015 Risk-free interest rate 1.36 % 1.82 % Volatility factor 66.26 % 65.78 % Weighted average expected life (in years) 7 7 Dividend rate 0.0 % 0.0 %

Stock Warrants (Tables)

Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2016
Stock Warrants [Abstract]
Schedule Of Warrant Activity [Table Text Block]	Weighted Average Weighted Average Remaining Shares Exercise Price Contractual Life (in years) Outstanding at December 31, 2015 71,342,894 $ 0.77 2.37 Granted 60,435,862 $ 0.21 2.65 Exercised (4,912,500) - Cancelled or expired (4,390,375) $ 2.01 Outstanding at December 31, 2016 122,475,881 $ 0.43 2.13
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes information about stock warrants at December 31, 2016: Warrants Outstanding Weighted Average Remaining Weighted Average Exercise Price Outstanding Contractual Life (in years) Exercise Price $ 0.075 5,367,319 $ 0.09 19,632,396 $ 0.10 590,000 $ 0.1125 19,632,396 $ 0.25 4,808,145 $ 0.26 7,500,000 $ 0.30 2,845,000 $ 0.33 7,875,001 $ 0.35 14,831,098 $ 0.38 741,000 $ 0.40 1,040,000 $ 0.45 1,730,000 $ 0.50 2,250,523 $ 0.75 11,556,394 $ 0.80 1,602,500 $ 1.10 18,866,850 $ 1.12 263,750 $ 2.00 138,800 $ 2.20 98,320 $ 2.25 1,106,389 $0.075 - $2.25 122,475,881 2.13 $ 0.43

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The valuation allowance is based on management’s current estimates of taxable income for the jurisdictions in which we operate and the period over which the deferred tax assets will be recoverable. December 31, 2016 December 31, 2015 Current deferred income tax asset: Tax net operating loss carry forward $ 29,846,911 $ 26,751,533 Tax-deferred stock option expense 1,256,810 1,164,784 Total current deferred income tax asset 31,103,721 27,916,317 Valuation Allowance (31,103,721) (27,916,317) Net deferred income tax asset $ - $ -

Lease Commitments (Tables)

Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2016
Leases [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum rental payments are as follows for the year ending December 31, 2015: Year ending Future minimum rental payments 2016 (payment in arrears) $ 21,754 2017 185,317 2018 189,613 2019 188,813 2020 184,813 2021 & Thereafter 369,626

Description of Company and Na32

Description of Company and Nature of Business (Details Textual) - USD ($)	Sep. 09, 2016	Sep. 08, 2016	Oct. 31, 2016	Sep. 26, 2016	May 27, 2016	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Nov. 30, 2016	Aug. 31, 2016	Jan. 01, 2016	Dec. 18, 2015
Nature of Business [Line Items]
Increase (Decrease) in Accounts Payable								$ 458,049	$ 148,619
Debt Instrument, Maturity Date			Feb. 28, 2017
Estimated Number Of Common Stock Shares To Be Issued					3,100,000
Estimated Value Of Common Stock To Be Issued					$ 15,000,000
Long-term Line of Credit						$ 3,000,000	$ 3,000,000	$ 3,000,000	$ 3,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						37,531,458		37,531,458	200,000
Proceeds From Issuance Of Common Stock						$ 1,407,430		$ 1,108,296	$ 1,112,303
Equity Method Investment, Ownership Percentage						1.70%		1.70%
Common Stock, Capital Shares Reserved for Future Issuance												12,500,000	7,500,000
Expected Number Of Shares To Be Issued						85,724,996		85,724,996
Proceeds from Sale of Equity Method Investments								$ 1,502,100	910,000
Proceeds from Related Party Debt			$ 255,000
Accounts Payable, Trade, Current						$ 1,796,416		1,796,416	$ 1,338,367
Common Stock [Member]
Nature of Business [Line Items]
Stock Issued During Period, Shares, New Issues						18,765,729
License Agreement Terms [Member]
Nature of Business [Line Items]
Accounts Payable, Trade, Current						$ 1,503,966		$ 1,503,966
AzurRx BioPharma Inc [Member]
Nature of Business [Line Items]
Equity Method Investment, Ownership Percentage						33.00%		33.00%	25.00%		1.70%
Sale of Stock, Number of Shares Issued in Transaction								125,757
Common Stock, Capital Shares Reserved for Future Issuance						100,000		100,000
Sale of Stock, Price Per Share						$ 1		$ 1
Proceeds from Sale of Equity Method Investments							$ 1,502,100	$ 1,502,100	$ 910,000
Unsecured Convertible Note [Member]
Nature of Business [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				20.00%
Debt Instrument, Maturity Date				Mar. 26, 2017
Debt Instrument, Face Amount				$ 156,250
Proceeds from Issuance of Debt				107,500
Long-term Debt, Gross				$ 125,000
Summer 2016 Notes [Member]
Nature of Business [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Instrument, Maturity Date	Mar. 31, 2017
Debt Instrument, Face Amount	$ 1,892,500		91,250
Long-term Debt, Gross	$ 1,987,125		$ 95,813
September 2016 Oid Secured Promissory Note [Member] | promissory note [Member]
Nature of Business [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		10.00%				10.00%		10.00%
Debt Instrument, Maturity Date								Oct. 15, 2016
Debt Instrument, Face Amount		$ 720,000
Proceeds from Issuance of Debt		$ 650,000
Exchange Notes [Member]
Nature of Business [Line Items]
Debt Instrument, Face Amount										$ 30,000
Long-term Debt, Gross										$ 31,500
Past Due 90 Days [Member]
Nature of Business [Line Items]
Increase (Decrease) in Accounts Payable								$ 1,503,966
Overdue Terms [Member]
Nature of Business [Line Items]
Increase (Decrease) in Accounts Payable								$ 1,652,009

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventory:
Finished goods	$ 8,725	$ 12,650
Work in progress	83,519	98,437
Total Inventory	$ 92,244	$ 111,087

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2016
Leaseholds and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Depreciation Methods	Life of lease
Computer [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Minimum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Summary of Significant Accoun35

Summary of Significant Accounting Policies (Details 2) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Lab equipment	$ 5,698,009	$ 6,617,038
Computer equipment	552,423	540,212
Office equipment	191,248	191,248
Leasehold improvements	212,730	212,730
Property, Plant and Equipment, Gross	6,654,410	7,561,228
Accumulated depreciation	(4,188,285)	(4,934,321)
Property and equipment, net	$ 2,466,125	$ 2,626,907

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Details 3) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Deposits	$ 19,041	$ 5,248
Other noncurrent assets	$ 19,041	$ 5,248

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Details 4) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Gross Revenue	$ 2,446,795	$ 1,861,802
Molecular Information Services [Member]
Segment Reporting Information [Line Items]
Gross Revenue	1,778,006	929,076
LAESI Instrument Platform [Member]
Segment Reporting Information [Line Items]
Gross Revenue	358,334	640,060
Research Products [Member]
Segment Reporting Information [Line Items]
Gross Revenue	$ 310,455	$ 292,666

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Details 5) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Payables And Accruals [Line Items]
Accrued expenses	$ 68,411	$ 28,112
Accrued interest	264,507	108,731
Accrued warranties	45,000	50,000
Accrued payroll and benefits	119,619	124,183
Accrued sales tax	103	616
Unearned revenue	58,407	79,666
Other payables and accrued expenses	$ 556,047	$ 391,308

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Details 6) - Derivative Financial Instruments, Liabilities [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Expected Volatility Rate	81.62%	75.54%
Probability of Future Capital Raises	100.00%	100.00%
Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Expected Term	3 months	2 years
Fair Value Assumptions, Risk Free Interest Rate	0.51%	0.16%
Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Expected Term	5 years	3 years 3 months 29 days
Fair Value Assumptions, Risk Free Interest Rate	1.20%	1.31%

Summary of Significant Accoun40

Summary of Significant Accounting Policies (Details 7) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	$ 3,097,921	$ 962,401
Derivative liabilities - Convertible Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	226,998
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	3,097,921	962,401
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - Convertible Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	226,998
Derivative liabilities - common stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	2,016,370	777,002
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	2,016,370	777,002
Derivative liabilities - warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	854,553	185,399
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	$ 854,553	$ 185,399

Summary of Significant Accoun41

Summary of Significant Accounting Policies (Details 8) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	$ 962,401
Issuance of warrants	527,900	$ 609,103
Ending Balance	3,097,921	962,401
Derivative liabilities - Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ending Balance	226,998
Derivative liabilities - Convertible Debt [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	0
Issuance of warrants	0
Anti-dilution shares to be issued	0
Unrealized (gain) loss on derivative liabilities	0
Fair value of variable conversion rate for convertible debentures issued in 2016	226,998
Fair value of derivative liabilities associated with other financial instruments issued in 2016	0
Ending Balance	226,998	0
Derivative liabilities - warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	185,399
Ending Balance	854,553	185,399
Derivative liabilities - warrant [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	185,399	65,187
Issuance of warrants	6,878	5,948
Anti-dilution shares to be issued	(1,044,420)	0
Unrealized (gain) loss on derivative liabilities	1,380,974	79,883
Fair value of variable conversion rate for convertible debentures issued in 2016	0
Fair value of derivative liabilities associated with other financial instruments issued in 2016	325,722
Recognition of derivative liabilities		34,381
Ending Balance	854,553	185,399
Derivative liabilities - common stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	777,002
Ending Balance	2,016,370	777,002
Derivative liabilities - common stock [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	777,002	88,871
Issuance of warrants	0	0
Anti-dilution shares to be issued	(6,429,375)	(945,451)
Unrealized (gain) loss on derivative liabilities	7,668,743	1,551,703
Fair value of variable conversion rate for convertible debentures issued in 2016	0
Fair value of derivative liabilities associated with other financial instruments issued in 2016	0
Recognition of derivative liabilities		81,879
Ending Balance	2,016,370	777,002
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	962,401
Ending Balance	3,097,921	962,401
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	962,401	154,058
Issuance of warrants	6,878	5,948
Anti-dilution shares to be issued	(7,473,795)	(945,451)
Unrealized (gain) loss on derivative liabilities	9,049,717	1,631,586
Fair value of variable conversion rate for convertible debentures issued in 2016	226,998
Fair value of derivative liabilities associated with other financial instruments issued in 2016	325,722
Recognition of derivative liabilities		116,260
Ending Balance	3,097,921	962,401
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ending Balance	226,998
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	185,399
Ending Balance	854,553	185,399
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - common stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	777,002
Ending Balance	$ 2,016,370	$ 777,002

Summary of Significant Accoun42

Summary of Significant Accounting Policies (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Aug. 31, 2016	Jan. 01, 2016	Dec. 18, 2015
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		185,501,000	77,317,000
Allowance for Doubtful Accounts Receivable		$ 7,000	$ 3,000
Accrued Warranty Expense		$ 45,000	50,000
Equity Method Investment, Ownership Percentage		1.70%
Depreciation, Depletion and Amortization, Total		$ 678,538	$ 686,820
Anti Dilutive Trigger Price		$ 0.075	$ 0.25
Proceeds from Sale of Equity Method Investments		$ 1,502,100	$ 910,000
Common Stock, Capital Shares Reserved for Future Issuance						12,500,000	7,500,000
Asset Impairment Charges		$ 122,894	$ 0
Series A Preferred Stock [Member]
Significant Accounting Policies [Line Items]
Sale of Stock, Number of Shares Issued in Transaction				100
Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		53.00%
AzurRx BioPharma Inc [Member]
Significant Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage		33.00%	25.00%		1.70%
Sale of Stock, Number of Shares Issued in Transaction		125,757
Proceeds from Sale of Equity Method Investments	$ 1,502,100	$ 1,502,100	$ 910,000
Equity Method Investment, Shares Sold		1,706,941	606,667
Common Stock, Capital Shares Reserved for Future Issuance		100,000
Sale of Stock, Price Per Share		$ 1
AzurRx BioPharma Inc [Member] | Common Stock [Member]
Significant Accounting Policies [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion		2,439,365	2,439,365
Large Pharmaceutical Company [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		22.00%

Bank Line of Credit (Details Te

Bank Line of Credit (Details Textual) - USD ($)	1 Months Ended		12 Months Ended
	Oct. 31, 2016	Jun. 20, 2016	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity (in dollars)			$ 3,000,000
Line of Credit Facility, Interest Rate Description			The interest rate is variable and equal to 0.75% plus prime with a minimum rate of 5.87% per annum.
Line of Credit Facility, Amount Outstanding (in dollars)			$ 3,000,000	$ 3,000,000	$ 3,000,000
Interest Payable, Current			264,507		$ 108,731
Debt Instrument, Maturity Date	Feb. 28, 2017
Line of Credit [Member]
Line of Credit Facility [Line Items]
Interest Payable, Current			$ 14,675
Debt Instrument, Maturity Date		Jul. 12, 2018

Loans Payable to Stockholders (

Loans Payable to Stockholders (Details Textual) - USD ($)

Mar. 14, 2017

Oct. 31, 2016

Sep. 30, 2016

Jul. 31, 2016

Jun. 30, 2016

Mar. 20, 2015

Mar. 31, 2015

Jul. 31, 2016

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

May 20, 2016

Jun. 03, 2014

Loans Payable to Stockholders [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.375

Repayments of Debt

$ 902,783

$ 193,415

Debt Conversion, Converted Instrument, Shares Issued

205,791

66,667

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

37,531,458

200,000

Warrants and Rights Outstanding

$ 101,177

Repayments of Related Party Debt

$ 5,444

$ 0

Debt Conversion, Original Debt, Amount

$ 51,448

$ 5,000

Debt Instrument, Convertible, Conversion Price

$ 0.075

Due to Officers or Stockholders, Current

$ 3,087,956

2,574,500

Payments of Debt Issuance Costs

330,141

309,345

Proceeds from Related Party Debt

$ 255,000

Debt Instrument, Maturity Date

Feb. 28, 2017

Interest Payable, Current

264,507

$ 108,731

Interest Expense [Member]

Loans Payable to Stockholders [Line Items]

Repayments of Notes Payable

$ 12,500

Interest Bearing Promissory Notes [Member]

Loans Payable to Stockholders [Line Items]

Due to Related Parties, Current

255,000

Due to Officers or Stockholders, Current

1,111,556

Debt Instrument, Periodic Payment, Interest

$ 105,078

$ 5,444

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

540,156

Interest Payable, Current

9,729

Non interest Bearing Promissory Notes [Member]

Loans Payable to Stockholders [Line Items]

Due to Officers or Stockholders, Current

$ 1,721,400

Loans Payable One [Member]

Loans Payable to Stockholders [Line Items]

Payments of Debt Issuance Costs

$ 31,455

Convertible One-year Promissory Note [Member]

Loans Payable to Stockholders [Line Items]

Debt Instrument, Interest Rate, Effective Percentage

10.00%

Maximum [Member]

Loans Payable to Stockholders [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

4,912,500

Minimum [Member]

Loans Payable to Stockholders [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,637,500

Debt Instrument, Convertible, Conversion Price

$ 0.075

Subsequent Event [Member]

Loans Payable to Stockholders [Line Items]

Debt Instrument, Maturity Date

Aug. 28, 2017

Director [Member]

Loans Payable to Stockholders [Line Items]

Repayments of Related Party Debt

$ 51,040

Debt Instrument, Convertible, Conversion Price

$ 0.33

Due to Related Party Remaining Amount

1,400,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Stock Issued During Period, Shares, New Issues

90,910

Director [Member] | Convertible Promissory Note Due On December 31,2015 [Member]

Loans Payable to Stockholders [Line Items]

Proceeds from Related Party Debt

$ 200,000

Debt Instrument, Maturity Date

Dec. 31, 2015

Director [Member] | Convertible Promissory Note Due On March 31,2016 [Member]

Loans Payable to Stockholders [Line Items]

Proceeds from Related Party Debt

$ 25,000

Debt Instrument, Maturity Date

Mar. 31, 2016

Summit Resources Inc [Member] | Notes And Warrants 2014 [Member]

Loans Payable to Stockholders [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.50

$ 0.80

Debt Instrument, Face Amount

$ 1,415,000

Repayments of Debt

250,000

Accretion Expense

$ 7,227

10,950

Loans Payable

1,074,773

Due to Related Parties, Current

$ 1,415,000

Debt Conversion, Converted Instrument, Shares Issued

1,080,312

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,415,000

Debt Conversion, Original Debt, Amount

$ 165,000

Debt Instrument, Increase, Accrued Interest

$ 105,078

Debt Instrument, Convertible, Conversion Price

$ 0.25

Debt Conversion, Converted Instrument, Warrants or Options Issued

540,156

Due To Officers Or Stock holders Current Net Of Discount

917,000

Due to Officers or Stockholders, Current

1,000,000

Summit Resources Inc [Member] | Maximum [Member] | Notes And Warrants 2014 [Member]

Loans Payable to Stockholders [Line Items]

Long-term Debt, Gross

1,500,000

Summit Resources Inc [Member] | Minimum [Member] | Notes And Warrants 2014 [Member]

Loans Payable to Stockholders [Line Items]

Long-term Debt, Gross

$ 900,000

Directors and Stock holders [Member]

Loans Payable to Stockholders [Line Items]

Repayments of Related Party Debt

57,500

$ 115,000

Due to Related Party Remaining Amount

1,400,000

Due to Related Parties

$ 372,440

$ 1,402,500

$ 17,000

Long-term Debt (Details)

Long-term Debt (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	$ 5,967,129	$ 3,049,752
Less: current portion	(4,012,149)	(1,323,594)
Less: unamortized original issue discount	(22,001)	0
Less: unamortized debt issuance costs	(163,624)	0
Long-term portion	1,769,355	1,726,158
Unsecured Convertible Debentures [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	2,114,438	0
Note Payable To West Virginia Development Office [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	92,873	100,656
Note Payable To West Virginia Economic Development Authority, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	143,312	143,312
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	139,229	139,229
Note Payable To West Virginia Economic Development Authority, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	572,148	572,148
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	581,987	581,987
Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	290,000	290,000
Note Payable To West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	300,000	300,000
Note Payable to West Virginia Economic Development Authority, Series 3 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	168,362	168,362
Capital leases [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	928,530	754,058
September 10% OID Secured Promissory Note [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	480,000	0
September 2016 20% OID Note [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	156,250	0
Short Term Convertible Notes [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	$ 0	$ 0

Long-term Debt (Details 1)

Long-term Debt (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Schedule of Capitalization, Long-term Debt [Line Items]
2,017	$ 4,264,898
2,018	539,235
2,019	478,274
2,020	333,970
2021 & Thereafter	350,752
Total	$ 5,967,129	$ 3,049,752

Long-term Debt (Details Textual

Long-term Debt (Details Textual) - USD ($)	Sep. 09, 2016	Sep. 08, 2016	Sep. 06, 2016	Sep. 04, 2016	Mar. 04, 2016	Apr. 30, 2017	Mar. 31, 2017	Nov. 22, 2016	Oct. 31, 2016	Sep. 30, 2016	Sep. 30, 2016	Sep. 26, 2016	Jul. 29, 2016	Jun. 30, 2016	May 31, 2016	Feb. 29, 2016	Jan. 31, 2016	Dec. 31, 2013	Jun. 30, 2012	May 31, 2012	Apr. 30, 2012	Mar. 31, 2012	Dec. 31, 2010	Oct. 31, 2010	Aug. 31, 2009	Mar. 31, 2007	Nov. 30, 2016	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	May 20, 2016	Mar. 31, 2016
Debt Instrument [Line Items]
Debt Instrument, Maturity Date									Feb. 28, 2017
Debt Instrument, Collateral																			The note was secured by 50% of equipment
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																														37,531,458	200,000
Debt Instrument, Convertible, Conversion Price																														$ 0.075
Debt Conversion, Converted Instrument, Shares Issued											205,791																			66,667
Class of Warrant or Right, Exercise Price of Warrants or Rights																															$ 0.375
Payments of Debt Issuance Costs																														$ 330,141	$ 309,345
Debt Conversion, Converted Instrument, Amount																														0	2,953,420
Debt and Capital Lease Obligations, Total																														5,967,129	3,049,752
Interest Payable, Current																														264,507	108,731
Investor [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										6,510,001	6,510,001																	6,510,001	6,510,001
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 233,345																										$ 14,950
Placement Agent [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									5,367,320
Warrants Not Settleable in Cash, Fair Value Disclosure	54,447																										3,488
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 0.075
Warrant [Member] | Placement Agent [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										1,519,000	1,519,000																	1,519,000	1,519,000
Unsecured Convertible Debentures [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			10.00%										10.00%
Debt Instrument, Periodic Payment					$ 150,000																							$ 51,613	$ 150,000
Debt Instrument, Convertible, Conversion Price													$ 0.25
Debt Instrument, Face Amount													$ 63,750
Debt Conversion, Converted Instrument, Shares Issued					108,696
Unsecured Debt Original Issue Discount Percentage					23.00%
Proceeds from Issuance of Unsecured Debt					$ 500,000
Warrants Not Settleable in Cash, Fair Value Disclosure																																	$ 12,773
Accretion Expense										$ 104,947																		$ 38,019
Legal Fees					$ 5,000
Debt Conversion, Converted Instrument, Warrants or Options Issued					1,637,500											590,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.75											$ 0.40
Proceeds from Convertible Debt													$ 51,000
Debt Conversion, Converted Instrument, Amount	$ 1,987,125				$ 27,174																						$ 127,313
Debt Instrument, Interest Rate, Effective Percentage	10.00%																										10.00%
Debt and Capital Lease Obligations, Total																														$ 2,114,438	$ 0
Repayments of Unsecured Debt			$ 655,000	$ 655,000
Percentage of Closing Bid Price					70.00%
Unsecured Convertible Debentures [Member] | Investor [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross (in dollars)												$ 125,000
Debt Instrument, Interest Rate, Stated Percentage												10.00%
Debt Instrument, Maturity Date												Mar. 26, 2017
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												468,750
Debt Instrument, Convertible, Conversion Price										$ 0.25	$ 0.25	$ 0.25	$ 0.325															$ 0.25	$ 0.25	$ 0.325
Debt Instrument, Face Amount										$ 156,250	$ 156,250	$ 156,250	$ 63,750															$ 156,250	$ 156,250
Warrants Not Settleable in Cash, Fair Value Disclosure												$ 1,792	$ 731
Class of Warrant or Right, Exercise Price of Warrants or Rights													$ 75
Debt Instrument Original Issue Discount Percentage										20.00%	20.00%	20.00%	20.00%															20.00%	20.00%
Debt Instrument, Interest Rate, Effective Percentage												10.00%
Class Of Warrant Or Right Warrants Term													3 years
Class Of Warrant Or Right Percentage Of Securities Called By Warrants Or Rights												85.00%
Unsecured Convertible Debentures [Member] | Placement Agent [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												109,375	1,409,625
Warrants Not Settleable in Cash, Fair Value Disclosure													$ 3,077
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 239																		$ 0.25
Payments of Debt Issuance Costs												$ 15,000	$ 191,400
Debt Instrument Original Issue Discount Percentage										20.00%	20.00%																	20.00%	20.00%
Class Of Warrant Or Right Warrants Term													3 years
Unsecured Convertible Debentures [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price													$ 0.25
Second Quarter Two Thousand Sixteen Convertible Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	10.00%																													10.00%	10.00%
Debt Instrument, Maturity Date		Oct. 15, 2016
Debt Instrument, Face Amount		$ 720,000																												$ 1,950,000
Unsecured Debt Original Issue Discount Percentage																														20.00%
Proceeds from Issuance of Unsecured Debt																														$ 1,560,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																														$ 0.25
Debt Instrument Original Issue Discount																														$ 390,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger																														85.00%
Secured Debt Original Issue Discount Percentage		10.00%
Proceeds from Issuance of Secured Debt		$ 650,000
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Second Quarter 2016 Convertible Notes Due Jan 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount																														$ 605,000
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Second Quarter 2016 Convertible Notes Due Nov 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount																														448,750
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Second Quarter 2016 Convertible Notes Due Mar 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount																														481,250
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Second Quarter 2016 Convertible Notes Due Dec 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount																														415,000
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Warrant [Member] | Investor [Member]
Debt Instrument [Line Items]
Derivative, Fair Value, Net																														$ 306,231
Second Quarter Two Thousand Sixteen Convertible Notes [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																														$ 0.25
Convertible Note and Warrant [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																														491,250
Class of Warrant or Right, Exercise Price of Warrants or Rights																														$ 0.25
Payments of Debt Issuance Costs																														$ 2,456
Placement Agent Commission paid																														$ 60,000
September 2016 Oid Secureds Promissory Note [Member]
Debt Instrument [Line Items]
Short-term Debt								$ 480,000
Repayments of Short-term Debt								240,000
Interest Payable, Current								$ 12,467
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																4,912,500
Maximum [Member] | Warrant [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																														$ 2.25
Maximum [Member] | Unsecured Convertible Debentures [Member] | Warrant [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Warrants or Options Issued																590,000
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																1,637,500
Debt Instrument, Convertible, Conversion Price																														0.075
Minimum [Member] | Warrant [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																														$ 0.075
Notes Payable to West Virginia Development Office [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument																										8 years
Long-term Debt, Gross (in dollars)																										$ 685,000
Debt Instrument, Interest Rate, Stated Percentage																										3.00%
Number of Debt Instrument Periodic Payments																										96 months
Debt Instrument, Periodic Payment																										$ 8,035
Pledged Assets, Not Separately Reported, Other																										$ 1,057,167
Debt Instrument, Maturity Date																										Apr. 30, 2015
Debt Instrument, Collateral																									The note was secured by equipment
Notes Payable																											$ 5,964			$ 86,909
Notes Payable to West Virginia Economic Development Authority, Series 1 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument																									10 years
Long-term Debt, Gross (in dollars)																									$ 242,631
Debt Instrument, Interest Rate, Stated Percentage																									4.00%
Number of Debt Instrument Periodic Payments																									120 months
Debt Instrument, Periodic Payment																									$ 2,457						$ 1,832
Pledged Assets, Not Separately Reported, Other																									$ 531,522
Debt Instrument, Maturity Date																									Aug. 31, 2019
Debt Instrument, Collateral																									The note was secured by 50% of equipment
Debt Instrument, Annual Principal Payment																															$ 33,880
Debt Instrument, Interest Rate, Increase (Decrease)																															1.50%
Notes Payable to West Virginia Economic Development Authority, Series 1 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)																														1.50%
Note Payable to West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument																									10 years
Long-term Debt, Gross (in dollars)																									$ 242,630
Debt Instrument, Interest Rate, Stated Percentage																									3.25%
Number of Debt Instrument Periodic Payments																									120 months
Debt Instrument, Periodic Payment																	$ 2,404								$ 2,371						$ 1,832
Pledged Assets, Not Separately Reported, Other																									$ 531,522
Debt Instrument, Maturity Date																									Aug. 31, 2019
Debt Instrument, Collateral																									The note was secured by 50% of equipment
Debt and Capital Lease Obligations, Total																														$ 139,229	139,229
Note Payable to West Virginia Economic Development Authority, Series 2 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument																								10 years
Long-term Debt, Gross (in dollars)																								$ 900,000
Debt Instrument, Interest Rate, Stated Percentage																								3.26%						1.50%
Number of Debt Instrument Periodic Payments																								120 months
Debt Instrument, Periodic Payment																								$ 8,802							57,513
Pledged Assets, Not Separately Reported, Other																								$ 477,095
Debt Instrument, Maturity Date																								Oct. 31, 2020
Debt Instrument, Collateral																								The note was secured by equipment
Debt Instrument, Annual Principal Payment																															125,990
Debt Instrument, Interest Rate, Increase (Decrease)																														1.50%
Debt and Capital Lease Obligations, Total																														$ 572,148	572,148
Note Payable to West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument																							10 years
Long-term Debt, Gross (in dollars)																							$ 900,000
Debt Instrument, Interest Rate, Stated Percentage																							3.25%
Number of Debt Instrument Periodic Payments																							120 months
Debt Instrument, Periodic Payment																	$ 8,902						$ 8,781								57,513
Pledged Assets, Not Separately Reported, Other																							$ 1,098,249
Debt Instrument, Maturity Date																							Dec. 31, 2020
Debt Instrument, Collateral																							The note was secured by equipment
Long-term Debt, Contingent Payment of Principal or Interest																														2,016
Debt and Capital Lease Obligations, Total																														$ 581,987	581,987
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument																						18 months
Long-term Debt, Gross (in dollars)																						$ 290,000
Debt Instrument, Interest Rate, Stated Percentage																						6.00%
Debt Instrument, Maturity Date																						Sep. 30, 2013
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																						72,500
Debt Instrument, Convertible, Conversion Price																						$ 2
Debt and Capital Lease Obligations, Total																														290,000	290,000
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member] | Due on December 15, 2013 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment																					$ 100,000
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member] | Due on March 15, 2014 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment																		$ 100,000
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member] | Due on June 15, 2014 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment																		$ 190,000
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument																					3 months
Long-term Debt, Gross (in dollars)																					$ 400,000
Debt Instrument, Interest Rate, Stated Percentage																					10.00%
Debt Instrument, Periodic Payment																					$ 312,014
Debt Instrument, Maturity Date																					Jun. 30, 2012
Debt Instrument, Periodic Payment, Principal							$ 25,000														$ 100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																					88,889
Debt Instrument, Convertible, Conversion Price																					$ 0.50
Debt Instrument, Face Amount																					$ 300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																					$ 0.50
Proceeds from Issuance of Warrants																														10,000,000
Debt and Capital Lease Obligations, Total																														$ 300,000	300,000
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 2 [Member] | Unsecured Convertible Debentures [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal						$ 25,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										750,000	750,000																	750,000	750,000
Debt Instrument, Convertible, Conversion Price										$ 0.10	$ 0.10																	$ 0.10	$ 0.10
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 2 [Member] | Unsecured Convertible Debentures [Member] | Warrant [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price										$ 0.10	$ 0.10																	$ 0.10	$ 0.10
Note Payable to West Virginia Economic Development Authority, Series 3 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument																			10 years
Long-term Debt, Gross (in dollars)																			$ 200,000
Debt Instrument, Interest Rate, Stated Percentage																			2.00%
Number of Debt Instrument Periodic Payments																			120 months
Debt Instrument, Periodic Payment																			$ 1,840
Pledged Assets, Not Separately Reported, Other																			$ 447,320
Debt Instrument, Maturity Date																			Jun. 30, 2022	Nov. 30, 2014
Debt Instrument, Annual Principal Payment																															26,673
Debt Instrument, Interest Rate, Increase (Decrease)																														1.50%
Debt and Capital Lease Obligations, Total																														$ 168,362	168,362
Capital Leases [Member]
Debt Instrument [Line Items]
Leases Secured Equipment cost														$ 549,543																1,868,809
Debt and Capital Lease Obligations, Total																														$ 13,793
Capital Leases [Member] | Maximum [Member]
Debt Instrument [Line Items]
Imputed Interest Rate																														9.45%
Capital Leases [Member] | Minimum [Member]
Debt Instrument [Line Items]
Imputed Interest Rate																														5.86%
Convertible Promissory Notes with WVJITB [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount																														$ 200,000
Payments of Debt Issuance Costs															$ 2,478	$ 2,478
Payments of Debt Restructuring Costs																														2,500
Interest Expense, Long-term Debt																														$ 59,250
September 10% OID Secured Promissory Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																														10.00%
Debt and Capital Lease Obligations, Total																														$ 480,000	0
September 2016 20% OID Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																														20.00%
Debt and Capital Lease Obligations, Total																														$ 156,250	$ 0

Common Stock (Details)

Common Stock (Details) - USD ($)		1 Months Ended	12 Months Ended
		Mar. 31, 2016	Dec. 31, 2016		Dec. 31, 2015
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)		150,000
Par Value, Beginning Balance (in dollars per share)			$ 0.0001		$ 0.0001
Beginning Balance			$ 13,315
Issuance of stock for services			467,620		$ 544,630
Ending Balance			$ 16,247		$ 13,315
Common Stock [Member]
Class of Stock [Line Items]
Balance (in shares)			133,146,250		66,588,600
Issuance of stock, Shares issued (in shares)			3,567,666		2,005,430
Balance (in shares)			162,471,373		133,146,250
Par Value, Beginning Balance (in dollars per share)			$ 1		$ 0.0001
Issuance of stock, Par Value (in dollars per share)			$ 0.0001
Price Per Share, Beginning Balance (in dollars per share)			Various
Issuance of stock, Price Per Share (in dollars per share)					Various
Gross Proceeds, Beginning Balance (in dollars)			$ 58,393,786		$ 53,708,521
Gross Proceeds, Ending Balance (in dollars)			59,801,216		58,393,786
Value of Services Obtained, Beginning Balance (in dollars)			2,359,303		1,814,673
Value of Services Obtained, Ending Balance (in dollars)			2,951,293		2,359,303
Beginning Balance			13,315		6,659
Issuance of stock for services			356		201
Ending Balance			16,247		13,315
Additional Paid in Capital, Beginning Balance (in dollars)	[1]		60,740,153		55,516,535
Additional Paid in Capital, Ending Balance (in dollars)	[1]		$ 62,440,674		$ 60,740,153
Issuance of stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[2]		18,765,730		13,051,058
Issuance of stock, Par Value (in dollars per share)	[2]		$ 0.0001		$ 0.0001
Stock Options exercised, Par Value (in dollars per share)	[2]		$ 0.075		$ 0.25
Stock Options exercised, Gross Proceeds (in dollars)	[2]		$ 1,407,430		$ 3,262,765
Stock Options exercised, Value of Services Obtained (in dollars)	[2]		0		0
Issuance of stock for services	[2]		1,877		1,305
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[2]		$ 1,108,296		$ 3,261,460
Issuance of stock 1 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[3]		371,364		30,286,520
Issuance of stock, Par Value (in dollars per share)	[3]		$ 0.0001		$ 0.0001
Stock Options exercised, Par Value (in dollars per share)	[3]		$ 0.25		$ 0.25
Stock Options exercised, Gross Proceeds (in dollars)	[3]		$ 0		$ 0
Stock Options exercised, Value of Services Obtained (in dollars)	[3]		92,841		0
Issuance of stock for services	[3]		37		3,029
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[3]		$ 92,804		$ (2,650)
Issuance of stock 2 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[4]		3,567,666		15,524,642
Issuance of stock, Par Value (in dollars per share)	[4]		$ 0.0001		$ 0.0001
Stock Options exercised, Par Value (in dollars per share)			$ 0.25	[5]	$ 0.25	[4]
Price Per Share, Beginning Balance (in dollars per share)			Various
Stock Options exercised, Gross Proceeds (in dollars)	[4]		$ 0		$ 0
Stock Options exercised, Value of Services Obtained (in dollars)	[4]		467,620		0
Issuance of stock for services	[4]		356		1,552
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[4]		$ 467,264		$ (1,552)
Issuance of stock 3 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[5]		108,696		1,134,520
Issuance of stock, Par Value (in dollars per share)	[5]		$ 0.0001		$ 0.0001
Issuance of stock, Price Per Share (in dollars per share)	[5]				Various
Stock Options exercised, Gross Proceeds (in dollars)	[5]		$ 0		$ 0
Stock Options exercised, Value of Services Obtained (in dollars)	[5]		27,174		319,630
Issuance of stock for services	[5]		11		114
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[5]		$ 27,163		$ 319,516
Issuance of stock 4 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[6]		66,667		90,910
Issuance of stock, Par Value (in dollars per share)	[6]		$ 0.0001		$ 0.0001
Stock Options exercised, Par Value (in dollars per share)	[6]		$ 0.075		$ 0.33
Stock Options exercised, Gross Proceeds (in dollars)	[6]		$ 0		$ 0
Stock Options exercised, Value of Services Obtained (in dollars)	[6]		5,000		30,000
Issuance of stock for services	[6]		6		9
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[6]		$ 4,994		$ 29,991
Issuance of stock 5 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[7]		6,445,000		780,000
Issuance of stock, Par Value (in dollars per share)	[7]		$ 0.0001		$ 0.0001
Stock Options exercised, Par Value (in dollars per share)	[7]		$ 0.07047		$ 0.25
Stock Options exercised, Gross Proceeds (in dollars)	[7]		$ 0		$ 0
Stock Options exercised, Value of Services Obtained (in dollars)	[7]		(645)		195,000
Issuance of stock for services	[7]		645		78
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[7]		$ 0		$ 194,922
Issuance Of Stock 6 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[8]				5,690,000
Issuance of stock, Par Value (in dollars per share)	[8]				$ 0.0001
Stock Options exercised, Par Value (in dollars per share)	[8]				$ 0.25
Stock Options exercised, Gross Proceeds (in dollars)	[8]				$ 1,422,500
Stock Options exercised, Value of Services Obtained (in dollars)	[8]				0
Issuance of stock for services	[8]				569
Issuance of stock, Additional Paid in Capital (in dollars)	[1],[8]				$ 1,421,931
[1]	Balance does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
[2]	Shares issued for conversion of an aggregate of $2,841,085 principal amount and $394,173 of accrued interest on promissory notes/convertible debenture and $27,506 of accounts payable. Shares do not contain an anti-dilution provision.
[3]	Conversion of preferred stock and accrued dividends into shares of Common Stock and contain an anti-dilution provision.
[4]	Shares issued under certain anti-dilution privileges.
[5]	Shares issued to consultants for services rendered. Shares do not contain anti-dilution provision.
[6]	Shares issued to a director as a commitment fee as part of Promissory Note. Shares do not contain anti-dilution provision.
[7]	Shares issued to directors for compensation for their service to the Company. Share do not contain anti-dilution provision.
[8]	Shares issued contain an anti-dilution provision that expire upon the earlier of 1) three years from date of issuance or 2) uplisting to a senior stock exchange.

Common Stock (Details Textual)

Common Stock (Details Textual) - USD ($)	1 Months Ended						2 Months Ended			3 Months Ended	12 Months Ended
	Dec. 31, 2016	Oct. 31, 2016	Sep. 30, 2016	Jul. 31, 2016	Mar. 31, 2016	Feb. 29, 2016	Dec. 31, 2016	Nov. 30, 2016	Apr. 30, 2016	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jan. 31, 2017	May 20, 2016
Class of Stock [Line Items]
Shares Authorized Total	510,000,000						510,000,000				510,000,000
Common Stock, Shares Authorized	500,000,000						500,000,000				500,000,000	500,000,000
Preferred Stock, Shares Authorized	10,000,000						10,000,000				10,000,000	10,000,000
Debt Conversion, Original Debt, Amount			$ 51,448								$ 5,000
Common Stock, Par or Stated Value Per Share	$ 0.0001						$ 0.0001				$ 0.0001	$ 0.0001
Proceeds From Issuance Of Common Stock							$ 1,407,430				$ 1,108,296	$ 1,112,303
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	37,531,458						37,531,458				37,531,458	200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 0.375
Payments of Stock Issuance Costs		$ 71,960
Interest Percentage On Delay Payments		18.00%
Expected Number Of Shares To Be Issued	85,724,996						85,724,996				85,724,996
Debt Instrument, Convertible, Conversion Price	$ 0.075						$ 0.075				$ 0.075
Class of Warrant or Right, Outstanding	49,459,532						49,459,532				49,459,532
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	450,000						450,000				450,000
Debt Conversion, Converted Instrument, Shares Issued			205,791								66,667
Stock Issued During Period, Shares, Issued For Services					150,000
Stock Issued During Period, Value, Issued For Services											$ 467,620	$ 544,630
Proceeds from Issuance of Private Placement		$ 5,000,000
Warrant To Purchase Common Stock							25,244,333
Directors compensation [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services											1,417,666
Consulting Service [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services											1,350,000
Accounts Payment conversion [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services											666,667
Issuance Cost [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services											133,333
Conversion Debt Principal Amount [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments											$ 2,841,085
Accrued Interest On Promissory Notes [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments											394,173
Conversion of Accounts Payable [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments											27,506
Consulting Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services	250,000
Consulting Fees	$ 30,000							$ 27,500
Consulting Agreement [Member] | Issue One [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.11
Stock Issued During Period, Shares, Issued For Services	250,000							500,000
Consulting Agreement [Member] | Issue Two [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								250,000
Stock Issued During Period, Shares, Issued For Services	200,000							25,000
Consulting Agreement [Member] | Issue Three [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services								250,000
Media Advertising [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services				300,000
Stock Issued During Period, Value, Issued For Services				$ 75,000
Convertible Notes Payable [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.40
Payments of Stock Issuance Costs						$ 945
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						450,000
Debt Conversion, Description						In February 2016, the Companys Board of Directors authorized the conversion of an aggregate of $33,333 of accrued interest on promissory notes issued by the Company to Summit and $8,060 of account payable (or a total of $41,393) by the Company to Summit, into 165,573 shares of Common Stock at the rate of $0.25 per share.
Loans Payable [Member]
Class of Stock [Line Items]
Debt Conversion, Original Debt, Amount	$ 5,000										$ 5,000
Debt Instrument, Convertible, Conversion Price	$ 0.075						$ 0.075				$ 0.075
Debt Conversion, Converted Instrument, Shares Issued	66,667										66,667
Derivative, Fair Value, Net	$ 5,480						$ 5,480				$ 5,480
Media Advertising Agreement [Member]
Class of Stock [Line Items]
Management Fee Expense									$ 37,500
Accounts Payable [Member]
Class of Stock [Line Items]
Debt Conversion, Original Debt, Amount	$ 50,000		$ 9,781
Debt Instrument, Convertible, Conversion Price	$ 0.075		$ 0.25				$ 0.075				$ 0.075
Debt Conversion, Converted Instrument, Shares Issued	666,667
Derivative, Fair Value, Net	$ 54,800						$ 54,800				$ 54,800
Interest Payable [Member]
Class of Stock [Line Items]
Debt Conversion, Original Debt, Amount			$ 41,667
Minimum [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														1,637,500
Partial Liquidated Damages Percentage		1.00%
Debt Instrument, Convertible, Conversion Price	$ 0.075						$ 0.075				$ 0.075
Maximum [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														4,912,500
Partial Liquidated Damages Percentage		6.00%
Investor [Member]
Class of Stock [Line Items]
Proceeds From Issuance Of Common Stock							$ 1,407,430
Number Of Units Sold							140.74
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			6,510,001
Placement Agent [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		5,367,320
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.075
Common Stock [Member]
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share	$ 1						$ 1				$ 1	$ 0.0001
Stock Issued During Period, Shares, New Issues											18,765,730	5,690,000
Stock Issued During Period, Shares, Issued For Services											3,567,666	2,005,430
Stock Issued During Period, Value, Issued For Services											$ 356	$ 201
Common Stock [Member] | Media Advertising Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services					150,000
Subsequent Event [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized													750,000,000
Preferred Stock, Shares Authorized													10,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right										250,000
Stock Issued During Period, Shares, Issued For Services										750,000
Subsequent Event [Member] | Investor [Member]
Class of Stock [Line Items]
Proceeds From Issuance Of Common Stock										$ 688,000
Number Of Units Sold										68.80
Subsequent Event [Member] | Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services										666,667
Private Placement [Member]
Class of Stock [Line Items]
Number Of Units Sold		500
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 10,000
Proceeds from Issuance of Private Placement		$ 5,000,000
Private Placement [Member] | Investor Warrants [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		133,333,334
Private Placement [Member] | Class B Warrnats [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		133,333.33
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.1125
Private Placement [Member] | Class A Warrnats [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		133,333.33
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.09
Private Placement [Member] | Placement Agent [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,328,001
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.075
Payments of Stock Issuance Costs		$ 186,132
Private Placement [Member] | Common Stock [Member]
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.0001
Stock Issued During Period, Shares, New Issues		66,666,667

Preferred Stock (Details)

Preferred Stock (Details)	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001
Share Price (in dollars per share) | $ / shares		$ 2
Issuance of stock, Gross Proceeds	$ 0	$ 575,042
Balance at December 31, 2014, Par Value (in value)	0
Issuance of stock, Par Value (in value)	0	2,953,420
Stock dividend, Par Value (in value)		0
Balance at December 31, 2015, Par Value (in value)	0	0
Additional Paid-in Capital [Member]
Class of Stock [Line Items]
Stock dividend, Par Value (in value)		156,048
Balance at December 31, 2014, Additional paid in Capital	$ 0	6,675,118
Issuance of stock, Additional Paid in Capital		740,063
Stock dividend, Additional paid in Capital		156,048
Conversion of preferred stock, Additional paid in Capital		(7,571,229)
Balance at December 31, 2015, Additional paid in Capital		$ 0
Preferred Stock [Member]
Class of Stock [Line Items]
Balance (in shares) | shares	0	3,337,725
Issuance of stock | shares		370,050
Stock dividend | shares		78,040
Conversion of preferred stock | shares		(3,785,815)
Balance (in shares) | shares		0
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001
Share Price (in dollars per share) | $ / shares	$ 2
Balance at December 31, 2014, Gross Proceeds	$ 0	$ 6,675,452
Issuance of stock, Gross Proceeds		740,100
Stock dividend, Gross Proceeds		(156,056)
Conversion of preferred stock, Gross Proceeds		(7,259,496)
Balance at December 31, 2015, Gross Proceeds		0
Balance at December 31, 2014, Par Value (in value)		334
Issuance of stock, Par Value (in value)		37
Stock dividend, Par Value (in value)		8
Conversion of preferred stock, Par Value (in value)		$ (379)
Preferred Stock [Member] | Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001
Share Price (in dollars per share) | $ / shares	2
Preferred Stock [Member] | Stock Dividend [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	0.0001
Share Price (in dollars per share) | $ / shares	2
Preferred Stock [Member] | Issuance of stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	0.0001
Share Price (in dollars per share) | $ / shares	$ 2

Preferred Stock (Details Textua

Preferred Stock (Details Textual) - $ / shares	1 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2016
Class of Stock [Line Items]
Share Price		$ 2
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.375
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		200,000	37,531,458
Preferred Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Convertible Preferred Stock, Per Share	$ 0.25
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		50,000
Preferred Stock, Dividend Rate, Percentage		6.00%

Stock Options and Stock-based52

Stock Options and Stock-based Compensation (Details) - Employee Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding	10,050,086	7,019,750
Shares, Granted	3,350,000	3,957,836
Shares, Exercised	0	0
Shares, Cancelled or expired	(2,620,000)	(927,500)
Shares, Outstanding	10,780,086	10,050,086	7,019,750
Shares Exercisable	5,680,899	4,938,664
Weighted Average Exercise Price, Outstanding	$ 0.69	$ 0.92
Weighted Average Exercise Price, Granted	0.15	0.33
Weighted Average Exercise Price, Cancelled or expired	0.52	0.9
Weighted Average Exercise Price, Outstanding	0.57	0.69	$ 0.92
Weighted Average Exercise Price, Exercisable	$ 0.84	$ 1.01
Weighted Average Remaining Contractual Life (in years), Outstanding	7 years 3 months 18 days	7 years 3 months 4 days	6 years 8 months 8 days
Weighted Average Remaining Contractual Life (in years), Exercisable		5 years 8 months 12 days	5 years 7 months 2 days

Stock Options and Stock-based53

Stock Options and Stock-based Compensation (Details 1)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Exercise Price 0.15 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.15
Options Outstanding (in shares)	3,250,000
Options Exercisable (in shares)	203,125
Exercise Price 0.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.25
Options Outstanding (in shares)	1,573,336
Options Exercisable (in shares)	774,586
Exercise Price 0.48 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.48
Options Outstanding (in shares)	150,000
Options Exercisable (in shares)	46,875
Exercise Price 0.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.50
Options Outstanding (in shares)	79,000
Options Exercisable (in shares)	79,000
Exercise Price 0.53 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.53
Options Outstanding (in shares)	405,000
Options Exercisable (in shares)	151,875
Exercise Price 0.55 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.55
Options Outstanding (in shares)	3,312,000
Options Exercisable (in shares)	2,414,688
Exercise Price 1.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 1.25
Options Outstanding (in shares)	150,000
Options Exercisable (in shares)	150,000
Exercise Price 1.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 1.50
Options Outstanding (in shares)	1,646,000
Options Exercisable (in shares)	1,646,000
Exercise Price 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 2
Options Outstanding (in shares)	214,750
Options Exercisable (in shares)	214,750
Exercise Price 0.25 - 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Limit (in dollars per share) | $ / shares	$ 0.25
Options Outstanding, Exercise Price, Upper Limit (in dollars per share) | $ / shares	$ 2
Options Outstanding (in shares)	10,780,086
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	7 years 3 months 18 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.57
Options Exercisable (in shares)	5,680,899
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.84

Stock Options and Stock-based54

Stock Options and Stock-based Compensation (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Nonvested, Beginning Balance	5,111,422	2,423,283
Shares, Granted	3,350,000	3,957,836
Shares, Forfeited	(1,594,216)	(927,500)
Shares, Vested	(1,526,519)	(342,197)
Shares, Nonvested at Ending Balance	5,340,687	5,111,422
Weighted Average Grant-date Fair Value, Nonvested, Beginning Balance	$ 0.153	$ 0.258
Weighted Average Grant-date Fair Value, Granted	0.153	0.155
Weighted Average Grant-date Fair Value, Forfeited	0.314	0.386
Weighted Average Grant-date Fair Value, Vested	0.076	0.283
Weighted Average Grant-date Fair Value, Nonvested, Ending Balance	$ 0.125	$ 0.153

Stock Options and Stock-based55

Stock Options and Stock-based Compensation (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 236,087	$ 267,638
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	222,195	230,016
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 13,892	$ 37,622

Stock Options and Stock-based56

Stock Options and Stock-based Compensation (Details 4)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.36%	1.82%
Volatility factor	66.26%	65.78%
Weighted average expected life (in years)	7 years	7 years
Dividend rate	0.00%	0.00%

Stock Options and Stock-based57

Stock Options and Stock-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jan. 01, 2016	Dec. 18, 2015	Dec. 31, 2012	Dec. 31, 2002
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 0
Share-based Compensation Arrangement by Share-based Payment Award Estimated Fair Value of Stock Price (in dollars per share)	$ 0.12
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in dollars)	$ 235,965	$ 267,638
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.153	$ 0.155
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Expected Term	2 years 6 months 7 days
Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested And Expected To Vest Fair Value	$ 612,632
Common Stock, Capital Shares Reserved for Future Issuance			12,500,000	7,500,000
Equity Incentive Plan 2002 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					4,150,000	450,000
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	5,000,000

Stock Warrants (Details)

Stock Warrants (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Shares, Outstanding at December 31, 2015	71,342,894
Shares, Granted	60,435,862
Shares, Exercised	(4,912,500)
Shares, Cancelled or expired	(4,390,375)
Shares, Outstanding at December 31, 2016	122,475,881	71,342,894
Weighted Average Exercise Price, Outstanding at December, 2015	$ 0.77
Weighted Average Exercise Price, Granted	0.21
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Cancelled or expired	2.01
Weighted Average Exercise Price,Shares, Outstanding at December 31, 2016	$ 0.43	$ 0.77
Weighted Average Remaining Contractual Life (in years), Outstanding	2 years 1 month 17 days	2 years 4 months 13 days
Weighted Average Remaining Contractual Life (in years), Granted	2 years 7 months 24 days

Stock Warrants (Details 1)

Stock Warrants (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)		$ 0.375
Warrants Outstanding (in shares)	49,459,532
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	122,475,881
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	2 years 1 month 17 days	2 years 4 months 13 days
Warrant Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.43	$ 0.77
Warrant [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	2.25
Warrant [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	0.075
Warrant [Member] | Exercise Price 0.075
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.075
Warrants Outstanding (in shares)	5,367,319
Warrant [Member] | Exercise Price 0.09
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.09
Warrants Outstanding (in shares)	19,632,396
Warrant [Member] | Exercise Price 1.12
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 1.12
Warrants Outstanding (in shares)	263,750
Warrant [Member] | Exercise Price 0.10
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.10
Warrants Outstanding (in shares)	590,000
Warrant [Member] | Exercise Price 0.1125
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.1125
Warrants Outstanding (in shares)	19,632,396
Warrant [Member] | Exercise Price 0.25
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.25
Warrants Outstanding (in shares)	4,808,145
Warrant [Member] | Exercise Price 0.26
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.26
Warrants Outstanding (in shares)	7,500,000
Warrant [Member] | Exercise Price 0.30
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.30
Warrants Outstanding (in shares)	2,845,000
Warrant [Member] | Exercise Price 0.33
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.33
Warrants Outstanding (in shares)	7,875,001
Warrant [Member] | Exercise Price 0.35
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.35
Warrants Outstanding (in shares)	14,831,098
Warrant [Member] | Exercise Price 0.38
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.38
Warrants Outstanding (in shares)	741,000
Warrant [Member] | Exercise Price 0.40
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.40
Warrants Outstanding (in shares)	1,040,000
Warrant [Member] | Exercise Price 0.45
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.45
Warrants Outstanding (in shares)	1,730,000
Warrant [Member] | Exercise Price 0.50
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.50
Warrants Outstanding (in shares)	2,250,523
Warrant [Member] | Exercise Price 0.75
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.75
Warrants Outstanding (in shares)	11,556,394
Warrant [Member] | Exercise Price 0.80
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.80
Warrants Outstanding (in shares)	1,602,500
Warrant [Member] | Exercise Price 1.10
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 1.10
Warrants Outstanding (in shares)	18,866,850
Warrant [Member] | Exercise Price 2.00
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2
Warrants Outstanding (in shares)	138,800
Warrant [Member] | Exercise Price 2.20
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.20
Warrants Outstanding (in shares)	98,320
Warrant [Member] | Exercise Price 2.25
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.25
Warrants Outstanding (in shares)	1,106,389
Warrant [Member] | Exercise Price 0.07-2.25
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	122,475,881

Stock Warrants (Details Textual

Stock Warrants (Details Textual) - USD ($)	Mar. 04, 2016	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Nov. 30, 2016	Oct. 31, 2016	Sep. 26, 2016	Sep. 09, 2016	Jul. 29, 2016	May 20, 2016	Mar. 31, 2016	Feb. 29, 2016	Dec. 31, 2015	Mar. 31, 2012
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)		49,459,532			49,459,532		49,459,532
Class of Warrant or Right, Exercise Price of Warrants or Rights																$ 0.375
Debt Conversion, Original Debt, Amount			$ 51,448				$ 5,000
Debt Conversion, Converted Instrument, Shares Issued			205,791				66,667
Debt Instrument, Convertible, Conversion Price		$ 0.075			$ 0.075		$ 0.075
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		450,000			450,000		450,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		37,531,458			37,531,458		37,531,458									200,000
Expected Number Of Shares To Be Issued		85,724,996			85,724,996		85,724,996
Warrants To Purchase Common Stock					25,244,336
Unsecured Convertible Debentures [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75														$ 0.40
Debt Conversion, Converted Instrument, Shares Issued	108,696
Debt Instrument, Convertible, Conversion Price												$ 0.25
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		6,841,569			6,841,569		6,841,569
Warrants Not Settleable in Cash, Fair Value Disclosure														$ 12,773
Accretion Expense				$ 104,947		$ 38,019
Loans Payable [Member]
Class of Warrant or Right [Line Items]
Term Of Warrants							18 months
Debt Conversion, Original Debt, Amount		$ 5,000					$ 5,000
Debt Conversion, Converted Instrument, Shares Issued		66,667					66,667
Debt Instrument, Convertible, Conversion Price		$ 0.075			$ 0.075		$ 0.075
Derivative, Fair Value, Net		$ 5,480			$ 5,480		$ 5,480
Accounts Payable [Member]
Class of Warrant or Right [Line Items]
Interest Expense, Other							$ 202,982
Term Of Warrants		18 months
Debt Conversion, Original Debt, Amount		$ 50,000	$ 9,781
Debt Conversion, Converted Instrument, Shares Issued		666,667
Debt Instrument, Convertible, Conversion Price		$ 0.075	$ 0.25	$ 0.25	$ 0.075	$ 0.25	$ 0.075
Derivative, Fair Value, Net		$ 54,800			$ 54,800		$ 54,800
Class A Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.09			$ 0.09		$ 0.09
Term Of Warrants					18 months
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		18,765,729			18,765,729		18,765,729
Class A Warrant [Member] | Loans Payable [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.09			$ 0.09		$ 0.09
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		66,667			66,667		66,667
Class A Warrant [Member] | Accounts Payable [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.09			$ 0.09		$ 0.09
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		66,667			66,667		66,667
Class B Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.1125			$ 0.1125		$ 0.1125
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		18,765,729			18,765,729		18,765,729
Class B Warrant [Member] | Loans Payable [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.1125			$ 0.1125		$ 0.1125
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		66,667			66,667		66,667
Class B Warrant [Member] | Accounts Payable [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.1125			$ 0.1125		$ 0.1125
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		66,667			66,667		66,667
Placement Agent [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 0.075
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									5,367,320
Warrants Not Settleable in Cash, Fair Value Disclosure								$ 3,488			$ 54,447
Placement Agent [Member] | Unsecured Convertible Debentures [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.25			$ 0.25		$ 0.25			$ 239
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										109,375		1,409,625
Warrants Not Settleable in Cash, Fair Value Disclosure												$ 3,077
Debt Instrument Original Issue Discount Percentage			20.00%	20.00%		20.00%
Investor [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			6,510,001	6,510,001		6,510,001
Warrants Not Settleable in Cash, Fair Value Disclosure								$ 14,950			$ 233,345
Investor [Member] | Unsecured Convertible Debentures [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 75
Debt Instrument, Convertible, Conversion Price		$ 0.325	$ 0.25	$ 0.25	$ 0.325	$ 0.25	$ 0.325			$ 0.25		$ 0.325
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										468,750
Warrants Not Settleable in Cash, Fair Value Disclosure										$ 1,792		$ 731
Debt Instrument Original Issue Discount Percentage			20.00%	20.00%		20.00%				20.00%		20.00%
St George Investment [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								6,445,000
Convertible Promissory Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]
Class of Warrant or Right [Line Items]
Debt Instrument, Convertible, Conversion Price																	$ 2
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1,180,000			1,180,000		1,180,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																	72,500
Minimum [Member]
Class of Warrant or Right [Line Items]
Debt Instrument, Convertible, Conversion Price		$ 0.075			$ 0.075		$ 0.075
Class of Warrant or Right, Number of Securities Called by Warrants or Rights													1,637,500
Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights													4,912,500
Summit Resources Inc [Member]
Class of Warrant or Right [Line Items]
Debt Instrument Original Issue Discount Percentage			20.00%	20.00%		20.00%
Common Stock [Member] | Unsecured Convertible Debentures [Member]
Class of Warrant or Right [Line Items]
Debt Instrument, Convertible, Conversion Price												$ 0.25
Common Stock [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right Term of Warrants or Rights							0.075
Common Stock [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right Term of Warrants or Rights							$ 2.25
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)		122,475,881			122,475,881		122,475,881
Warrant [Member] | Loans Payable [Member]
Class of Warrant or Right [Line Items]
Derivative, Fair Value, Net		$ 5,480			$ 5,480		$ 5,480
Warrant [Member] | Placement Agent [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,519,000	1,519,000		1,519,000
Warrant [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.075			$ 0.075		$ 0.075
Warrant [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.25			$ 2.25		$ 2.25

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current deferred income tax asset:
Tax net operating loss carry forward	$ 29,846,911	$ 26,751,533
Tax-deferred stock option expense	1,256,810	1,164,784
Total current deferred income tax asset	31,103,721	27,916,317
Valuation Allowance	(31,103,721)	(27,916,317)
Net deferred income tax asset	$ 0	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Operating Loss Carryforwards, Expiration Dates	expire beginning 2021 for both federal and state purposes.
Income Tax Examination, Likelihood of Unfavorable Settlement	greater than 50% likelihood
Operating Loss Carryforwards	$ 76,530,000	$ 68,600,000
Deferred Tax Assets, Valuation Allowance	$ 31,103,721	$ 27,916,317

Lease Commitments (Details)

Lease Commitments (Details)	Dec. 31, 2016USD ($)
Lease Commitments [Line Items]
2016 (payment in arrears)	$ 21,754
2,017	185,317
2,018	189,613
2,019	188,813
2,020	184,813
2021 & Thereafter	$ 369,626

Lease Commitments (Details Text

Lease Commitments (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Lease Commitments [Line Items]
Description of Lessor Leasing Arrangements, Operating Leases		13,969
Operating Leases, Rent Expense (in dollars)		$ 167,633	$ 274,580
Article IV-Possession [Member]
Lease Commitments [Line Items]
Operating Leases, Rent Expense		$ 13,969
Article IV-Possession [Member] | Subsequent Event [Member]
Lease Commitments [Line Items]
Operating Leases, Rent Expense	$ 15,401
Increase In Operating Leases Rent Expense Per Month	$ 1,432
Maximum [Member]
Lease Commitments [Line Items]
Lessee Leasing Arrangements, Operating Leases, Term of Contract		5 years

Retirement Plan (Details Textua

Retirement Plan (Details Textual)	12 Months Ended
	Dec. 31, 2016
Retirement Plan [Line Items]
Description of Postemployment Benefits	The Company provides a 401(k) Profit Sharing Plan for elective deferrals whereby participants can defer up to 100% of their wages not to exceed a maximum dollar amount determined by the Federal Government each year.

Commitments and Contingencies (

Commitments and Contingencies (Details Textual)	Nov. 04, 2016USD ($)	Jan. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2016EUR (€)
Loss Contingencies [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident (in dollars)					$ 5,000,000
Royalty Expenses					8,000	$ 3,000
Accrued warranties			$ 45,000		45,000	50,000
Payments to Acquire Projects					24,296
Accounts Payable, Current			41,000		41,000	30,000
Loss Contingency, Estimate of Possible Loss			213,032		213,032
Minimum Base Rent Expenses	$ 90,801
MPR [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Amount			161,889.16
Settlement Liabilities, Current			111,889.16		111,889.16
Subsequent Event [Member] | MPR [Member]
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss		$ 37,000
Loss Contingency, Damages Paid, Value		$ 111,889.16
First Payment [Member] | MPR [Member]
Loss Contingencies [Line Items]
Payments for Legal Settlements			25,000
Second Payment [Member] | MPR [Member]
Loss Contingencies [Line Items]
Payments for Legal Settlements			25,000
Omics2image [Member]
Loss Contingencies [Line Items]
Payments to Acquire Projects					76,858	46,600
George Washington University [Member]
Loss Contingencies [Line Items]
Royalty Expenses					24,319	41,500
License Costs					25,000
Minimum License Diligence Resources Year Two					12,500
Minimum License Diligence Resources After Year Two					20,000
License and Maintenance Revenue				$ 30,000	$ 30,000
Royalties Percentage on Net Sales of Licensed Products					7.00%
Royalties Percentage on Combination Products for Combined Cumulative Net Sales					5.00%
Sales Revenue, Services, Net					$ 50,000,000
Reduce Royalties Percentage After Net Sales of Licensed Products					6.00%
Reduce Royalties Percentage on Combination Products for Combined Cumulative After Net Sales					4.00%
Minimum Royalties Year One			1,500		$ 1,500
Minimum Royalties Year Two			2,500		2,500
Minimum Royalties Year Three			3,500		3,500
Minimum Royalties Year After Three Year			6,000		6,000
Accrued Royalties, Current			76,858		76,858	54,693
Accounts Payable, Current			85,883		85,883
Dynamic Manufacturing LLC [Member]
Loss Contingencies [Line Items]
Commitments Outstanding			$ 53,063		$ 53,063
COAST Project [Member]
Loss Contingencies [Line Items]
Commitments Outstanding | €							€ 60,000
LAESI Instruments [Member]
Loss Contingencies [Line Items]
Accrued warranties						$ 50,000

Evaluation of Subsequent Even67

Evaluation of Subsequent Events (Details Textual) - USD ($)	Apr. 07, 2017	Sep. 30, 2017	Jan. 31, 2017	Oct. 31, 2016	Sep. 30, 2016	Mar. 31, 2016	Dec. 31, 2016	Mar. 31, 2017	Jul. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Proceeds from Related Party Debt				$ 255,000
Warrants To Purchase Common Stock							25,244,336
Common Stock, Par or Stated Value Per Share							$ 0.0001			$ 0.0001	$ 0.0001
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.375
Payments of Stock Issuance Costs				71,960
Conversion of convertible debt										$ 0	$ 2,953,420
Stock Issued During Period, Shares, Issued For Services						150,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							37,531,458			37,531,458	200,000
Debt Instrument, Convertible, Conversion Price							$ 0.075			$ 0.075
Proceeds From Issuance Of Common Stock							$ 1,407,430			$ 1,108,296	$ 1,112,303
Debt Conversion, Converted Instrument, Shares Issued					205,791					66,667
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right							450,000			450,000
Proceeds from Issuance of Private Placement				$ 5,000,000
Common Stock, Shares Authorized							500,000,000			500,000,000	500,000,000
Debt Conversion, Original Debt, Amount					$ 51,448					$ 5,000
Payments To Acquire Machinery and Equipment										$ 120,241	$ 119,254
Scenario, Forecast [Member]
Subsequent Event [Line Items]
Conversion of convertible debt		$ 308,439
Stock Issued During Period, Shares, Issued For Services								250,000
Common Stock To Be Issued								250,000
Consulting Agreement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued For Services										250,000
Placement Agent [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.075
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				5,367,320
Investor [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					6,510,001
Proceeds From Issuance Of Common Stock							$ 1,407,430
Number Of Units Sold							140.74
West Virginia Jobs Investment Trust Board [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					590,000
Warrant [Member] | Placement Agent [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,519,000
Common Stock [Member]
Subsequent Event [Line Items]
Common Stock, Par or Stated Value Per Share							$ 1			$ 1	$ 0.0001
Stock Issued During Period, Shares, New Issues										18,765,730	5,690,000
Stock Issued During Period, Shares, Issued For Services										3,567,666	2,005,430
Private Placement [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 10,000
Number Of Units Sold				500
Proceeds from Issuance of Private Placement				$ 5,000,000
Private Placement [Member] | Class A Warrnats [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.09
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				133,333.33
Private Placement [Member] | Class B Warrnats [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.1125
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				133,333.33
Class Of Warrants Or Rights Expiration Term				5 years
Private Placement [Member] | Investor Warrants [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				133,333,334
Private Placement [Member] | Placement Agent [Member]
Subsequent Event [Line Items]
Warrants To Purchase Common Stock				2,448,001
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.075
Payments of Stock Issuance Costs				$ 186,132
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				2,328,001
Private Placement [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Common Stock, Par or Stated Value Per Share				$ 0.0001
Stock Issued During Period, Shares, New Issues				66,666,667
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued For Services								750,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								250,000
Common Stock To Be Issued								500,000
Common Stock, Shares Authorized			750,000,000
Subsequent Event [Member] | Stockholder Notes One [Member]
Subsequent Event [Line Items]
Conversion of convertible debt								$ 2,521,719
Debt Instrument, Convertible, Conversion Price								$ 0.075
Debt Conversion, Converted Instrument, Shares Issued								34,853,829
Interest Payable								$ 92,319
Subsequent Event [Member] | Senior Secured Convertible Note [Member]
Subsequent Event [Line Items]
Proceeds from Related Party Debt	$ 200,000								$ 1,550,000
Debt Instrument, Periodic Payment, Principal	$ 62,030.86
Debt Instrument, Convertible, Conversion Price	$ 0.075
Debt Instrument, Face Amount	$ 1,750,000
Debt Instrument, Term	36 years
Percentage of Equity Proceeds Agreed to Prepay the Loan	30.00%
Related Party Debt, Prepayments of Loan by Equity Offering	$ 500,000
Related Party Debt Mandatory Prepayment, Equity Offering Limit	5,000,000
Payments To Acquire Machinery and Equipment	$ 1,250,000
Debt Instrument, Frequency of Periodic Payment	monthly installments
Debt Instrument, Interest Rate Terms	interest at the rate of 15% per annum), or (b) 20% of the cash proceeds we receive from customers who request services from the Company using the new mass spectrometer equipment. We also agreed to establish a special lock box to deposit cash proceeds we receive from use of such equipment.
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	85.00%
Subsequent Event [Member] | Class B Warrnats [Member] | Remaining Debt One [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0
Subsequent Event [Member] | Class of Warrant or Right,Exercise Price One [Member] | Stockholder Notes One [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.09
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								34,853,829
Term Of Warrants								18 months
Subsequent Event [Member] | Class of Warrant or Right,Exercise Price One [Member] | Stockholder Notes Two [Member]
Subsequent Event [Line Items]
Term Of Warrants								18 months
Subsequent Event [Member] | Class of Warrant or Right,Exercise Price Two [Member] | Stockholder Notes One [Member]
Subsequent Event [Line Items]
Term Of Warrants								5 years
Subsequent Event [Member] | Class of Warrant or Right,Exercise Price Two [Member] | Stockholder Notes Two [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.1125
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								34,853,829
Term Of Warrants								5 years
Subsequent Event [Member] | Class of Warrant or Right,Exercise Price Three [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.09
Term Of Warrants								18 months
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								666,667
Subsequent Event [Member] | Class of Warrant or Right,Exercise Price Three [Member] | Stockholder Notes Three [Member]
Subsequent Event [Line Items]
Term Of Warrants								18 months
Subsequent Event [Member] | Class of Warrant or Right,Exercise Price Four [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.1125
Term Of Warrants								5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								666,667
Subsequent Event [Member] | September 2016 Oid Secured Promissory Note [Member]
Subsequent Event [Line Items]
Repayments of Short-term Debt								$ 200,000
Short-term Debt								$ 280,000
Subsequent Event [Member] | Consulting Agreement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued For Services								1,200,000
One Time Retainer Payment For Service								$ 10,000
Subsequent Event [Member] | Director [Member]
Subsequent Event [Line Items]
Proceeds from Related Party Debt								522,148
Debt Conversion, Original Debt, Amount								$ 131,319
Subsequent Event [Member] | Board of Directors Chairman [Member]
Subsequent Event [Line Items]
Sale of Stock, Number of Shares Issued in Transaction								560,000
Sale of Stock, Price Per Share								$ 0.11
Subsequent Event [Member] | Investor [Member]
Subsequent Event [Line Items]
Proceeds From Issuance Of Common Stock								$ 688,000
Number Of Units Sold								68.80
Subsequent Event [Member] | West Virginia Jobs Investment Trust Board [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.10
Term Of Warrants								5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								750,000
Subsequent Event [Member] | MPR [Member]
Subsequent Event [Line Items]
Loss Contingency, Damages Paid, Value			$ 111,889.16
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Term Of Warrants								18 months
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued For Services								666,667
Common Stock, Conversion Price								$ 0.075
Subsequent Event [Member] | Common Stock [Member] | Consulting Agreement [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								1,720,000
Subsequent Event [Member] | Warrant One [Member]
Subsequent Event [Line Items]
Term Of Warrants								5 years